영문계약__글145건

  1. 2019.09.27 제품개발 및 공급계약에 따라 개발완료 후 시제품 납품 BUT 발주사에서 품질 성능 불량 주장하며 분쟁상황 – 법원은 제품 미완성으로 개발회사의 개발비용 및 대금청구 – 불인정: 특허법원 2..
  2. 2019.08.28 계약체결 목표로 상당한 투자 BUT 계약체결 전 사업관계 파탄 상황 - 계약성립 불인정 상황에서 불법행위로 인한 손해배상 책임
  3. 2019.08.27 계약체결 불발 책임 쟁점 - 중소기업지원 구매조건부 신제품 기술개발과제, RFP 과제 선정된 주관기관의 과제 수행 및 성공 후 발주처 지자체와 개발제품 구매계약 체결 불발 상황 – 지자체의..
  4. 2019.06.14 국제계약, 영문계약 실무 - 기술이전, 특허실시, 신제품 개발판매 계약서에서 상표라이선스 관련 계약 조항 샘플
  5. 2019.06.13 국제계약, 영문계약 상표사용허락 라이선스 계약서 샘플 – MIT 대학 로고 상표라이선스 계약서
  6. 2019.06.13 국제계약, 영문계약 실무 - 상표사용허락 라이선스 계약서 조항 샘플
  7. 2019.06.10 기술이전, 라이선스, 특허실시, 공동연구개발 국제계약, 영문계약 실무상 기본용어 설명 참고자료 – covenant, representation, warranty 의미, 위반책임 및 차이점
  8. 2019.06.10 기술이전, 라이선스, 특허실시, 공동연구개발 국제계약서, 영문계약서에서 TAX 세무조항, RECORD, AUDIT 회계자료 감사권한 관련 계약조항 샘플
  9. 2019.06.05 독점라이선스 국제계약서에서 계약종료 시 라이센시의 보상청구 관련 주요내용, 분쟁사례, 판결 및 중재판정 요지 및 실무적 포인트 몇 가지
  10. 2019.06.05 기술이전, 라이선스, 특허실시, 공동연구개발 등 국제계약서, 영문계약서에서 미국법 FCPA, Anti-Corruption, Compliance 관련 계약조항 샘플
  11. 2019.06.05 기술이전, 라이선스, 특허실시, 공동연구개발 등 국문계약서에서 공정의무, 반부패의무, 비위행위금지, Anti-Corruption, Compliance 관련 계약조항 샘플
  12. 2019.06.05 국제계약, 영문계약에서 Anti-Corruption, Compliance 쟁점, 미국법 FCPA 관련 주요내용, 최근 제재사례 및 실무적 포인트 몇 가지
  13. 2019.06.04 국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 계약종료, 계약해지, TERMINATION 영문조항 샘플
  14. 2019.06.04 국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 기술지원 TECHNICAL ASSISTANCE 조항 샘플
  15. 2019.05.31 특허기술, 영업비밀 실시허락, 기술이전, 라이선스 영문계약서에서 진술 및 보증조항 REPRESENTATIONS AND WARRANTIES 샘플
  16. 2019.05.29 특허실시, 기술이전, 공동연구개발, 라이선스 등 국제계약에서 분쟁해결수단 중재조항 관련된 분쟁사례 및 실무적 포인트 몇 가지
  17. 2019.05.29 대한상사중재원의 조정 (Mediation) 개요 설명 – 중재(Arbitration)와 엄격하게 구별
  18. 2019.05.29 중재법 주요조항 정리
  19. 2019.05.28 특허실시, 영업비밀, 기술이전 라이선스 및 생산공급 계약서에서 LICENSE GRANT 계약조항 샘플
  20. 2019.05.23 특허실시, 기술이전, 라이선스 영문계약서에서 진술보증, 면책조항 관련 실무적 포인트 몇 가지 + 면책조항 INDEMNIFICATION, INSURANCE, LIMITATION OF LIABILITY 계약조항 샘플
  21. 2019.05.23 특허실시, 기술이전 라이선스, 공동연구개발계약에서 추가 연구개발 결과물, 개량발명 관련 계약조항 샘플, 법적 쟁점 및 실무적 대응방안 몇 가지
  22. 2019.05.22 기술이전, 라이선스 계약에서 특허기술 사용대가 로열티 vs 기술지원 비용 로열티 구분 + 로열티 지급과 원천징수 문제
  23. 2019.05.22 미국연방대법원 2019. 5. 20. 선고 Mission Product vs Tempnology 판결 - 라이선스 계약서에서 계약해지 (termination) 사유 - 파산, bankruptcy 사유 발생 시 라이선스 계약의 종료 관련 라이센시의 권리 관계
  24. 2019.05.21 특허실시, 기술이전, 라이선스 계약서에서 TERMINATION 조항 – 라이센시 파산 등 일반사유 및 양 당사자의 계약위반으로 인한 계약종료, 계약종료 후 처리 등 계약조항 샘플
  25. 2019.05.21 라이선스 계약서에서 계약해지 (termination) 사유 - 부도, 압류 등 파산, bankruptcy 관련 사유 발생 시 라이선스 계약의 법률관계 – 미국연방대법원 2019. 5. 20. 선고 Mission Product vs Tempnology 판결
  26. 2019.05.20 기술이전, 특허 라이선스 계약서에서 진술 및 보증조항 REPRESENTATIONS AND WARRANTIES 계약조항 샘플
  27. 2019.05.20 [NDA분쟁] 비밀보호계약, 비밀유지약정, NDA, CDA에서 비밀보호대상 조항 위반여부 쟁점 미국소송 사례
  28. 2019.05.20 특허라이선스 계약에서 Licensee의 주문에 따라 특허발명의 전용품을 제조, 납품한 행위 – 특허간접침해에 해당하지 않음: 대법원 2019. 2. 28. 선고 2017다290095 판결
  29. 2019.05.18 기술이전, 라이선스 등 영문계약서에 사용되는 일반조항 GENERAL PROVISIONS 계약조항 샘플 (1)
  30. 2019.05.17 제약회사의 기술이전, 독점 라이선스, API 공급, 완제품 생산위탁, 완제품구매 계약서에서 개발, 생산, 판매 활동에 관한 JSC 관련 계약조항 영문 샘플

 

1. 사안의 개요

- 개발회사 원고 vs 발주회사 피고 - 원고가 기화식 소독기를 제작하여 피고 회사에 납품하기로 하는 제품공급계약 체결

- 원고회사에서 개발완료 및 시제품 납품

- 발주회사에서 제품 주문하지 않고 계약관계 파탄

 

계약조항

 

2. 원고 개발회사 주장요지

처음부터 개발비 지급 및 생산 발주 능력이 없는 상태에서 계약을 체결하고 원고의 디자인, 설계도면 및 영업비밀을 무단으로 제3자에게 제공하였음. 사기, 저작권법위반, 부정경쟁방지법 위반으로 고소하였는데, 검찰은 이에 대하여 불기소처분으로 종결

민사소송 제기 시제품 개발비용 지급청구 + 불법행위로 인한 손해배상 청구

 

3. 특허법원 판결요지

제작물 공급계약의 성질 판단기준 및 당사자의 권리의무 관련 법리

제작물공급계약은 대체로 매매와 도급의 성질을 함께 가지고 있으므로, 그 적용 법률은 계약에 의하여 제작 공급하여야 할 물건이 대체물인 경우에는 매매에 관한 규정이 적용되지만, 물건이 특정의 주문자의 수요를 만족시키기 위한 부대체물인 경우에는 당해 물건의 공급과 함께 그 제작이 계약의 주목적이 되어 도급의 성질을 띠게 된다.

 

제작물공급계약에서 보수의 지급시기에 관하여 당사자 사이의 특약이나 관습이 없으면 도급인은 완성된 목적물을 인도받음과 동시에 수급인에게 보수를 지급하는 것이 원칙이고, 이때 목적물의 인도는 완성된 목적물에 대한 단순한 점유의 이전만을 의미하는 것이 아니라 도급인이 목적물을 검사한 후 그 목적물이 계약내용대로 완성되었음을 명시적 또는 묵시적으로 시인하는 것까지 포함하는 의미이다.

 

한편, 도급계약에 있어 일의 완성에 관한 주장·입증책임은 수급인에게 있고, 수급인은 최후 공정을 일단 종료하였다는 점뿐만 아니라 그 목적물의 주요구조 부분이 약정된 대로 시공되어 사회통념상 일반적으로 요구되는 성능을 갖추고 있다는 점까지 주장·입증하여야 한다.

 

구체적 사안에 대한 판단

계약 내용에 따르면 기화식 소독기는 피고 회사의 수요를 만족하기 위해 제작되는 것이므로, 이 사건 계약은 특정 주문자의 수요를 만족시키기 위한 부대체물에 대한 제작물공급계약에 해당하여 도급의 성질을 띠게 되고, 원고는 개발비를 제품 납품가에 포함하여 피고 회사에 청구할 수 있도록 규정되어 있으므로, 결국 원고의 개발비용은 기화식 소독기가 피고 회사에 납품되어 그 납품대금을 지급받을 수 있을 때 지급받게 되는 것이다.

 

그런데 피고는 계속해서 원고측에 시제품 성능에 대해 문제를 제기하고 있던 상황이므로 원고가 일을 완성하여 피고들이 시제품 개발비용 지급의무를 부담한다고 볼 수 없다.

 

또한 피고의 기망행위를 전제로 한 원고의 주장은 나머지 점에 관하여 더 나아가 살필 필요 없이 이유 없고, 원고의 디자인 및 설계도면이 피고 회사에게도 전달된 사실은 인정되나, 피고들이 이를 무단으로 제3자에게 공급하고 이를 기초로 원고의 시제품과 동일 내지 유사한 제품을 생산하여 판매하였음을 인정할 증거가 없으므로, 이를 전제로 한 원고의 저작권침해 내지 영업비밀 침해 주장 역시 나머지 점에 관하여 더 나아가 살필 필요 없이 이유 없다.

 

첨부: 특허법원 2018. 10. 26. 선고 20181299 판결

 

KASAN_제품개발 및 공급계약에 따라 개발완료 후 시제품 납품 BUT 발주사에서 품질 성능 불량 주장하며 분쟁상황

특허법원 2018. 10. 26. 선고 2018나1299 판결.pdf

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.09.27 09:25
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

계약체결을 목표로 상당한 시간과 비용을 투자하였으나 여러 가지 이유로 계약서에 서명하기 전에 사업관계가 파탄나는 경우가 있습니다. 상당한 비용과 시간을 투입한 당사자는 상대방으로부터 아무것도 받지 못하고 그 손해를 온전히 감수한다고 억울함을 호소합니다. 무엇이든 손해를 회복할 방안은 없는지 권리구제수단을 문의하는 사례가 많습니다. 이와 같은 상황에 관한 법리와 사례를 간략하게 설명하면 다음과 같습니다. 

 

1. 계약상 책임 여부

 

계약자유의 원칙상 각 당사자는 그 의사에 따라 계약을 체결하거나 하지 않을 자유가 있습니다. 계약 과정에서 각자의 책임으로 관련 비용을 부담하는 것이 원칙입니다. 계약이 성립된 경우에만 비로소 계약상 책임이 발생합니다.

 

계약은 당사자 의사합치로 성립되는 것이므로 계약서 작성이나 서명, 날인 등은 성립요건이 아닙니다. 다만, 계약하겠다는 정도의 단순한 의사표시만으로는 계약이 성립되지 않습니다. 그 계약의 본질적 요소에 대한 당사자들 의사합치가 있어야만 합니다.

 

한편, 모든 요소에 대한 완전한 합의가 없었다고 해도 항상 계약이 불성립한 것은 아닙니다. 계약의 본질적 부분에 대한 합의가 있다면, 즉 합의되지 않은 부분이 계약의 본질적 부분에 해당하지 않을 경우라면, 합의된 부분만으로도 계약을 체결하였을 것이 인정되는 때에는 합의된 부분만으로 계약이 성립되었다고 봅니다.

 

분쟁사례로 대법원 2001. 6. 15. 선고 9940418 판결을 살펴보면, 공사도급계약에서 견적서, 이행각서, 계약보증서까지 제공하였더라도 정식 계약서를 날인하기 전에, 법원은 다음과 같은 이유로 그 계약성립을 인정하지 않았습니다.

 

"견적서는 계약 체결전 도급금액을 정하기 위한 준비행위의 성격을 가진다. 견적서를 채택하여 도급금액을 일단 정한 후 나머지 계약조건에 대하여도 합의를 하여 하도급계약을 최종적으로 완성하기로 한 것이다. 당사자들은 청약, 청약의 거절, 변경을 가한 승낙, 새로운 청약만을 교환하였을 뿐 의사의 합치는 없었다. 제출한 이행각서는 하도급계약이 성립할 경우에 이행을 하겠다는 것이고, 계약보증서도 장차 성립할 하도급계약의 이행을 담보하려는 취지에서 교부한 것에 불과하다."

 

계약이 성립되지 않았으므로 계약상 책임도 존재하지 않습니다. 일방 당사자가 이미 상당한 시간과 비용을 투입하였다고 해도 상대방에게 계약상 책임을 물을 수는 없습니다.

 

2. 불법행위 책임

 

계약협상 후 계약체결을 거절할 수 있지만 예외적으로 그 과정에서 불법행위 성립이 인정되면 불법행위로 인한 손해배상 책임을 인정할 수 있습니다.

 

대법원 2003. 4. 11. 선고 200153059 판결은 어느 일방이 교섭단계에서 계약이 확실하게 체결되리라는 정당한 기대 내지 신뢰를 부여하여 상대방이 그 신뢰에 따라 행동하였음에도 상당한 이유 없이 계약의 체결을 거부하여 손해를 입혔다면 이는 신의성실의 원칙에 비추어 볼 때 계약자유 원칙의 한계를 넘는 위법한 행위로서 불법행위를 구성한다고 판결하였습니다. 대법원 2001. 6. 15. 선고 9940418 판결도 계약상 책임은 부인하면서도 불법행위 책임을 인정하였습니다.

 

위 대법원 판결을 자세하게 분설하면, (1) 계약 협상의 한쪽 당사자("")가 상대방 당사자("")에게 교섭단계에서 계약이 확실하게 체결되리라는 정당한 기대 내지 신뢰를 부여하였고, (2) 그 상대방 당사자("")가 그와 같은 신뢰에 따라 구체적인 준비작업 등 행동을 취하였는데 불구하고, (3) 최초 신뢰를 부여한 ""이 상당한 이유 없이 계약의 체결을 거부함으로써, (4) 결국 ""에게 손해가 발생하였다면, ""은 신의성실의 원칙을 위반한 불법행위를 범하였으므로 그로 인한 손해배상책임을 진다는 것입니다.

 

어느 일방이 교섭단계에서 계약이 확실하게 체결되리라는 정당한 기대 내지 신뢰를 부여하여 상대방이 그 신뢰에 따라 행동하였음에도 상당한 이유 없이 계약의 체결을 거부하여 손해를 입혔다면 이는 신의성실의 원칙에 비추어 볼 때 계약자유 원칙의 한계를 넘는 위법한 행위로서 불법행위를 구성한다는 취지입니다. 다만, 계약자유의 원칙에 대한 예외적 책임이므로 엄격하게 제한적으로 적용합니다.

 

3. 손해배상의 범위

 

손해배상 책임이 인정된다고 하여도 그 범위는 계약이 유효하게 성립할 것으로 기대한 상대방이 투입하여 신뢰이익의 배상으로 한정됩니다. 즉 그러한 신뢰가 없었더라면 통상 지출하지 아니하였을 비용에 대하여만 배상할 책임이 있습니다. 계약 협상과정에서 통상 들어가는 비용, 즉 계약 체결여부와 무관하게 들어가는 비용까지 ""에게 책임을 물을 수 는 없습니다.

 

실제 사안에서 본다면, 손해배상범위는 계약성립을 믿고 지출된 특별한 손해에 한정되므로, 일반적으로 그 액수는 많지 않을 것입니다. 예외적으로 큰 액수의 손해발생을 주장하는 경우 그 손해배상을 청구하는 당사자가 특별한 사정의 존재를 주장 입증해야만 합니다.

 

4. 실무적 포인트  

 

계약교섭의 일방은 벤처, 오퍼상, 소규모 사업자, 소기업이고 상대방은 대기업이나 중견기업으로서 일방이 압도적 우위에 있는 경우에도 항상 계약자유의 원칙만을 강조한다면 현실과 동떨어진 공허한 소리에 가깝습니다. 계약자유의 원칙을 악용하여 상대방에서 상당한 시간과 비용을 투자한 결과를 쉽게 얻고 난 후 정식 계약을 체결하지 않는 방식으로 부당한 이익을 얻고 상대방에게 심각한 피해를 주는 사례도 많습니다. 계약서를 체결하기 전 상황에서 계약성립 인정 + 계약상 책임을 묻는 것을 기대하기 어렵습니다.

 

실무적으로 불법행위 책임을 묻는 것이 피해구제를 받는 유일한 방안입니다. 그러나 그것도 계약자유의 원칙에 대한 예외적 책임이므로 실무상 매우 엄격하고 제한적으로 허용됩니다. 현실적으로 권리구제에 성공할 가능성이 그리 높지 않다는 의미입니다.

 

그렇다고 다른 대안도 없습니다. 불법행위 성립요건을 엄밀하고 정확하게 검토하고 신중한 소송전략으로 대응해야만 원하는 피해구제를 받을 수 있을 것입니다. 참고로 상대방에게 비난할만한 사정이 있다고 해도 우리나라 손해배상 법리상 징벌적 손해배상 책임은 인정되지 않습니다. 앞서 설명한 것처럼 계약성립을 신뢰하여 지출한 비용이나 그로 인한 손해범위로 그치고 계약성립 및 이행을 가정한 이행이익을 넘지 못합니다.

 

KASAN_계약체결 목표로 상당한 투자 BUT 계약체결 전 사업관계 파탄 상황 - 계약성립 불인정 상황에서 불법행위

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.08.28 08:34
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

1. 구매조건부 신제품 기술개발과제 협약 체결

 

2. 기술개발과제 수행 및 경과

(1) 원고회사 주관기관 - 국책과제 기술개발과제 선정 - 정부출연금 184백만원 + 자기 부담금 투입

(2) 개발과제 수행 완료 후 성공 판정

(3) 그러나 발주처 지자체에서 신제품 구매계약 체결 거절

(4) 피고 지자체 상대로 민사소송 제기

(5) 원고 회사의 주장 요지 구매계약체결을 전제로 지자체의 채무불이행 책임 주장 + 예비적으로 구매계약 채결이 없다면 지자체의 계약체결상 과실 책임 내지 불법행위 책임 주장

 

3. 법원의 판단

1심 판결 수원지방법원 성남지원 2018. 1,. 26. 선고 2016가합1096 판결

2심 판결 서울고등법원 2018. 12. 19. 선고 20182013675 판결

판단 요지 계약성립 불인정, 채무불이행 책임 불인정 but 지자체의 불법행위 책임 인정 지자체에 대한 약 83백만원 손해배상 명령

 

4. 판결이유

(1) 계약체결 불인정

 

 

(2) 계약체결 과정상 불법행위 책임 인정

 

 

KASAN_계약체결 불발 책임 쟁점 - 중소기업지원 구매조건부 신제품 기술개발과제, RFP 과제 선정된 주관기관의

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.08.27 16:45
Trackback 0 : Comment 0

댓글을 달아 주세요


 

0. TRADEMARKS.

10.1 Licensed Product Marks.

(a) LICENSEE and LICENSOR agree that (i) LICENSEE shall be responsible for the selection, registration and maintenance of all Trademarks which it employs in connection with the Commercialization of any Licensed Product in the Territory under this Agreement and (ii) LICENSOR shall be responsible for the selection, registration and maintenance of all Trademarks which it employs in connection with the Commercialization of any Licensed Product outside of the Territory under this Agreement;

 

provided that each Party shall use Commercially Reasonable Efforts to differentiate Licensed Products from products marketed as of the Closing by, for example, not utilizing any Trademark in connection with the Commercialization of any Licensed Product that would be confusingly similar to any Trademark utilized in connection with the Commercialization of products marketed as of the Effective Date but, provided further that, neither Party shall be obligated to utilize, or not to utilize, any Trademark if, in such Party’s sole opinion, such utilization would (i) have a material adverse impact on Commercialization of such Licensed Product or (ii) result in material delay in achieving Regulatory Approval for Commercialization of such Licensed Product.

 

(b) Subject to Section 10.1(a), LICENSEE shall own and control all Trademarks which it employs in connection with the Commercialization of any Licensed Product in the Territory under this Agreement (“LICENSEE Licensed Product Marks”) and shall pay all costs relating thereto.

 

LICENSEE shall have the right to brand the Licensed Products in the Territory using LICENSEE Licensed Product Marks it determines appropriate for the Licensed Products, which may vary by country or within a country, and shall have the right, but no obligation, to use the LICENSOR Trademarks, subject to the license granted by LICENSOR to LICENSEE with respect to the LICENSOR TRADEMARKS pursuant to Section 10.1(c), on the labeling and packaging for Licensed Products in the Territory, and on all marketing, advertising and promotional materials associated with such Licensed Products (collectively the “LICENSEE Licensed Product Materials”);

 

provided that LICENSEE shall not, and shall ensure that its Affiliates and Sublicensees will not, make any use of (i) the Trademarks or house marks of LICENSOR (including LICENSOR’s corporate name) other than the LICENSOR Trademarks or (ii) any trademark confusingly similar to the Trademarks or house marks of LICENSOR (including LICENSOR’s corporate name), in the case of both (i) and (ii), on any LICENSEE Licensed Product Materials. Subject to the license granted by LICENSOR to LICENSEE with respect to the LICENSOR TRADEMARKS pursuant to Section 10.1(c), LICENSEE shall own all rights in the LICENSEE Licensed Product Materials.

 

(c) Subject to the terms and conditions of this Agreement, during the Term of this Agreement, LICENSOR hereby grants to LICENSEE a non-exclusive, royalty-free, sublicenseable license (i) to use LICENSOR Trademarks on all LICENSEE Licensed Product Materials in the Territory and (ii) to reproduce, prepare derivative works, distribute copies, perform, display and otherwise use LICENSOR Copyrights in connection with the exercise of the rights granted by LICENSOR to LICENSEE under the terms of this Agreement. All representations of the LICENSOR Trademarks that LICENSEE intends to use shall first be submitted to LICENSOR for approval (which shall not be unreasonably withheld or delayed) of design, color, and other details or shall be exact copies of those used by LICENSOR. All representations of the LICENSOR Trademarks that are used by LICENSEE shall comply with the reasonable usage guidelines provided by LICENSOR.

 

(d) During the Term, LICENSOR may make a written request to LICENSEE for permission to use the LICENSEE Licensed Product Marks in relation to Licensed Products in Korea. If LICENSEE consents to such use (such consent not to be unreasonably withheld), the Parties shall discuss in good faith the terms and conditions applicable to such use of the LICENSEE Licensed Product Marks, including any reasonable consideration payable with respect to such use. In the event that LICENSEE provides its consent and the Parties agree upon terms and conditions applicable to such use, all representations of the LICENSEE Licensed Product Marks that LICENSOR intends to use shall first be submitted to LICENSEE for approval (which shall not be unreasonably withheld or delayed) of design, color, and other details or shall be exact copies of those used by LICENSEE, and all representations of the LICENSEE Licensed Product Marks that are used by LICENSOR shall comply with the usage guidelines provided by LICENSEE.

 

(e) Subject to Section 10.1(a), LICENSOR shall own and control all Trademarks which it employs in connection with the Commercialization of any Licensed Product outside the Territory and in Japan under this Agreement (“LICENSOR Licensed Product Marks”) and shall pay all costs relating thereto.

 

LICENSOR shall have the right to brand the Licensed Products outside the Territory and in Japan using LICENSOR Licensed Product Marks it determines appropriate for the Licensed Products, which may vary by country or within a country, and on the labeling and packaging for Licensed Products outside the Territory and in Japan, and on all marketing, advertising and promotional materials associated with such Licensed Products (collectively the “LICENSOR Licensed Product Materials”);

 

provided that LICENSOR shall not, and shall ensure that its Affiliates and sublicensees will not, make any use of (i) the Trademarks or house marks of LICENSEE (including LICENSEE’s corporate name) or (ii) any trademark confusingly similar to the Trademarks or house marks of LICENSEE (including LICENSEE’s corporate name), in the case of both (i) and (ii), on any LICENSOR Licensed Product Materials. LICENSOR shall own all rights in the LICENSOR Licensed Product Materials.

 

10.2 No Challenge.

(a) LICENSOR recognizes the exclusive ownership by LICENSEE of all LICENSEE Licensed Product Marks. LICENSOR shall not, either while this Agreement is in effect, or at any time thereafter, register, use or challenge or assist others to challenge the LICENSEE Licensed Product Marks. LICENSOR shall not attempt to obtain any right in or to any name, logotype, trademark or trade dress confusingly similar for the marketing, sale or distribution of any goods or products, notwithstanding whether such goods or products have a different use or are dissimilar to the Licensed Products.

 

(b) LICENSEE recognizes the exclusive ownership by LICENSOR of all LICENSOR Licensed Product Marks. LICENSEE shall not, either while this Agreement is in effect, or at any time thereafter, register, use or challenge or assist others to challenge the LICENSOR Licensed Product Marks. LICENSEE shall not attempt to obtain any right in or to any name, logotype, trademark or trade dress confusingly similar for the marketing, sale or distribution of any goods or products, notwithstanding whether such goods or products have a different use or are dissimilar to the Licensed Products.

 

10.3 Proceedings.

(a) Only LICENSEE will be authorized to initiate at its own discretion legal proceedings against any infringement or threatened infringement of any LICENSEE Licensed Product Marks.

 

(b) Only LICENSOR will be authorized to initiate at its own discretion legal proceedings against any infringement or threatened infringement of any LICENSOR Licensed Product Marks.

 

10.4 Domain Names.

(a) LICENSEE shall be responsible for the registration, hosting, maintenance and defense of any domain name based on the LICENSEE Licensed Product Marks. LICENSEE may at its sole and absolute discretion register in its own name or in name of others, host on its own servers or on Third Party servers, maintain and defend such domain names and use them for websites.

 

(b) LICENSOR shall be responsible for the registration, hosting, maintenance and defense of any domain name based on the LICENSOR Licensed Product Marks. LICENSOR may at its sole and absolute discretion register in its own name or in name of others, host on its own servers or on Third Party servers, maintain and defend such domain names and use them for websites.

 

KASAN_국제계약, 영문계약 실무 - 기술이전, 특허실시, 신제품 개발판매 계약서에서 상표라이선스 관련 계약 조항

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.06.14 09:11
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

 

T R A D E M A R K   L I C E N S E    A G R E E M E N T

 

This License Agreement ("Agreement") is effective as of the date above the signatures of the parties below("EFFECTIVE DATE") by and between the MIT, a corporation duly organized and existing under the laws of the Commonwealth of Massachusetts, having its principal office at 77 Massachusetts Avenue, Cambridge, Massachusetts, 02139, U.S.A. ("MIT"), and ____, a corporation duly organized under the laws of __, having its principal office at ___("LICENSEE").

 

1. BACKGROUND

1.1 MIT owns rights in certain marks now and previously used by MIT and has acquired public recognition and goodwill through the use of such marks.

 

1.2 LICENSEE recognizes the goodwill appurtenant to use of said marks and desires to obtain a license to use certain of such marks. MIT is willing to grant such a license under the terms and conditions of this Agreement.

 

2. DEFINITIONS

2.1 LICENSED MARKS shall mean those marks listed in Appendix A.

2.2 LICENSED PRODUCTS shall mean the products in the categories specified in Appendix B that bear a LICENSED MARK.

2.3 TERRITORY shall mean U.S.A. and Canada only.

2.4 NET SALES PRICE shall mean LICENSEE's billing price to customers or distributors, less (1)discounts given that are customary in the trade, (2) returns, (3) transportation charges on returns if paid by LICENSEE, (4) taxes, and (5) prepaid transportation charges on LICENSED PRODUCTS SOLD by LICENSEE.

2.5 SOLD (or SALE) shall mean the first to occur of a LICENSED PRODUCT being shipped, distributed, paid for, billed or invoiced.

2.6 TERM shall mean the effective period of this Agreement, which shall commence on the EFFECTIVE DATE and which shall terminate on the fifth anniversary of the EFFECTIVE DATE.

 

3. LICENSE GRANT

3.1 Subject to the terms and conditions of this Agreement, MIT grants to LICENSEE the nonexclusive right to use, sell and have sold LICENSED PRODUCTS in the TERRITORY during the TERM hereof. In addition, MIT grants to LICENSEE, during the TERM, the nonexclusive right to manufacture and have manufactured the LICENSED PRODUCTS within and outside the United States, provided that LICENSEE and any manufacturers with whom LICENSEE subcontracts comply with MIT's Code of Conduct, further described in Paragraph 3.3.

 

3.2 LICENSEE shall not sublicense any of the rights granted hereunder.

 

3.3 LICENSEE acknowledges that MIT desires that LICENSEE not engage in practices that adversely affect the dignity and welfare of the workers who manufacture or produce the LICENSED PRODUCTS. MIT has adopted a Code of Conduct that regulates the conditions of manufacture of LICENSED PRODUCTS.  MIT has attached the current version of the Code of Conduct as Appendix C hereto, thereby becoming a part of LICENSEE's obligations under this Agreement. MIT reserves the right to amend its Code of Conduct from time to time and attach it to this Agreement. Any LICENSEE who is unable or unwilling to comply with the amended Code of Conduct, as it exists from time to time, shall be allowed to terminate this Agreement within ninety (90) days after receipt of the revised Code of Conduct from MIT.

 

4. PAYMENTS

4.1 Delivered with LICENSEE's signed Agreement, LICENSEE shall pay to MIT a non- refundable License Issue Fee of One Hundred Dollars ($100.00). This fee is not creditable to future royalties due hereunder.

 

4.2 LICENSEE shall pay to MIT an annual non-refundable, non-creditable License Maintenance Fee of One Hundred Dollars ($100.00), due on each anniversary of the EFFECTIVE DATE during the TERM.

 

4.3 In addition to the License Issue Fee and annual License Maintenance Fee, LICENSEE shall pay to MIT a continuing royalty of seven and one half percent (7.5%) of the NET SALES PRICE of all LICENSED PRODUCTS SOLD by LICENSEE. If LICENSEE has SOLD any LICENSED PRODUCTS to any party affiliated with LICENSEE, or in any way directly or indirectly related to or under common control with LICENSEE, at a price less than the regular price charged to other parties, the royalties payable hereunder shall be computed on the basis of the regular price charged to nonaffiliated parties. There shall be no deduction from the royalties owed for uncollectible accounts or for advertising or other expenses of any kind which may be incurred or paid by LICENSEE, except those specifically enumerated in Paragraph 2.4 above.

 

4.4 Royalty payments shall be due within thirty (30) days of the end of each calendar quarter and shall be accompanied by the royalty reports described in Paragraph 5.2 below. Royalty payments shall be payable in United States dollars to "Massachusetts Institute of Technology" at the location in Paragraph 12.1 below, or at such other place as MIT may reasonably designate consistent with the laws and regulations controlling in any foreign country. If any currency conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by using the conversion rate existing in the United States, as reported in the Wall Street Journal, on the last working day of the calendar quarter of the reporting period to which such royalty payments relate.

 

4.5 The royalty payments set forth in this Agreement shall, if overdue, bear interest, to the extent permitted by law, at five (5) percentage points above the Prime Rate of interest as reported in the Wall Street Journal on the date payment is due. The payment of such interest shall not foreclose MIT from exercising any other rights it may have as a consequence of the lateness of any payment.

 

5. REPORTS AND RECORDS

5.1 LICENSEE shall keep full, true and accurate books of account containing all particulars that may be necessary for the purpose of showing the amounts payable to MIT hereunder. Such books of account shall be kept at LICENSEE's principal place of business or the principal place of business of the appropriate Division of LICENSEE to which this Agreement relates. 

 

Such books and the supporting data shall be open at all reasonable times for five (5) years following the end of the calendar year to which they pertain to the inspection of MIT or its agents for the purpose of verifying LICENSEE's royalty statement or compliance in other respects with this Agreement.

 

In the event that any audit performed under this paragraph reveals an underpayment in excess of five percent (5%), LICENSEE shall bear the full cost of such audit and shall remit any amounts due to MIT within thirty (30) days of receiving notice thereof from MIT.

 

5.2 Within thirty (30) days after each calendar quarter during the TERM, LICENSEE shall deliver to MIT true and accurate reports giving such particulars of the business conducted by LICENSEE during the preceding calendar quarter as shall be pertinent to a royalty accounting hereunder. These reports shall include at least the following: (a) A description, broken out under each individual trademark, of all LICENSED PRODUCTS manufactured and SOLD. (b) Total billings, broken out under each individual trademark, for LICENSED PRODUCTS SOLD. (c) Deductions applicable as provided in Paragraph 2.4. (d) Total royalties due. (e) Names and addresses of LICENSEE's retail sellers of LICENSED PRODUCTS.

 

5.3 With each such report submitted, LICENSEE shall pay to MIT the royalties due and payable under this Agreement. If no royalties shall be due, LICENSEE shall so report.

 

6. TERMINATION

6.1 MIT may terminate this Agreement immediately upon written notice to LICENSEE upon the following: (a) If LICENSEE shall cease to carry on its business; (b) In the event LICENSEE fails to submit timely reports or payments due hereunder, and fails to submit such reports or make such payments within thirty (30) days after receiving written notice of such failure; (c) If, after expiration of the ninety (90) day grace period set forth in Paragraph 3.3, LICENSEE fails to comply with MIT's adopted Code of Conduct or any changes thereto; or (d) In the event LICENSEE commits a material breach of its obligations under this Agreement, except for breach as described in (a) through (c) of this Paragraph, and fails to cure that breach within ninety (90) days after receiving written notice of such breach.

 

6.2 LICENSEE may terminate this Agreement for any reason, (i) upon at least six (6) months prior written notice to MIT, such notice to state the date at least six (6) months in the future upon which termination is to be effective, and (ii) upon payment of all amounts due to MIT through such termination effective date.

 

6.3 Upon termination of this Agreement for any reason, nothing herein shall be construed to release either party from any obligation that matured prior to the effective date of such termination. The following provisions shall survive the expiration or termination of this Agreement: Articles 2, 7, 10 and 13, and Paragraphs 5.1, 5.2 (obligation to provide final report and payment), 6.3, and 6.4.

 

6.4 Upon expiration or termination of this Agreement, all rights granted to LICENSEE hereunder shall cease, and LICENSEE shall refrain from further use of the LICENSED MARKS in any manner. LICENSEE acknowledges that failure to comply with this provision shall result in immediate and irreparable harm affording injunctive and any and all other appropriate relief to MIT.

 

6.5 Upon expiration or termination of this Agreement, LICENSEE shall not operate its business in any manner which would falsely suggest to the public that this Agreement is still in force or that any relationship exists between LICENSEE and M.I.T.

 

7. GOODWILL IN LICENSED MARKS

7.1 LICENSEE agrees that the essence of this Agreement is founded on the goodwill associated with the LICENSED MARKS and value of that goodwill in the minds of the consuming public. LICENSEE agrees that it is critical that such goodwill be protected and enhanced and, toward this end, LICENSEE shall not during the TERM or thereafter:

(a) attack the title or any rights of MIT in or to the LICENSED MARKS; (b) apply to register or maintain any application or registration of the LICENSED MARKS or any other mark confusingly similar thereto in any jurisdiction, domestic or foreign; (c) use any colorable imitation of any of the LICENSED MARKS, or any variant form (including variant design forms, logos, colors, or typestyles) of the LICENSED MARKS not specifically approved by MIT; (d) misuse the LICENSED MARKS; (e) take any action that would bring the LICENSED MARKS into public disrepute; (f) use the LICENSED MARKS, or any mark or name confusingly similar thereto, in its corporate or trade name; or (g) take any action that would tend to destroy or diminish the goodwill in the LICENSED MARKS.

 

7.2 All use by LICENSEE of the LICENSED MARKS shall inure to the benefit of MIT.

 

7.3 LICENSEE agrees to cooperate fully with MIT in securing and maintaining the goodwill of MIT in the LICENSED MARKS.

 

7.4 Upon becoming aware of any third party infringement of the LICENSED MARKS, LICENSEE shall promptly advise MIT of such infringement, including the name and location of such infringer.

 

8. QUALITY CONTROL; PACKAGING AND ADVERTISING APPROVAL

8.1 All LICENSED PRODUCTS shall be of a quality acceptable to MIT LICENSEE acknowledges that if LICENSED PRODUCTS manufactured and SOLD by it are of inferior quality in design, material or workmanship, the substantial goodwill that MIT possesses in the LICENSED MARKS would be impaired.

 

Accordingly, LICENSEE agrees that all LICENSED PRODUCTS shall be of high quality. To this end, LICENSEE shall furnish to MIT, free of cost, for its approval, a sample of each LICENSED PRODUCT, together with any carton or container, packing or wrapping material.  MIT shall have fourteen (14) days from receipt of each LICENSED PRODUCT in which to approve the sample.

 

In absence of approval, the sample shall be deemed as rejected as an example of the quality for the LICENSED PRODUCT. The LICENSED MARKS may be applied by LICENSEE only to such LICENSED PRODUCTS as are manufactured in accordance with the corresponding samples accepted hereunder and that have substantially the same relative quality position in the market place as do the samples thereof; provided, however, LICENSEE may furnish to MIT a further sample of any LICENSED PRODUCT of which it desires to change the quality, style and/or appearance and MIT shall have fourteen (14) days from receipt thereof in which to approve in writing said further sample. Failure to approve shall be deemed rejection thereof as an example of quality for that LICENSED PRODUCT.

 

MIT shall have the right through its employee(s) or designated representative(s) during normal business hours to inspect the facilities and product inventory of LICENSEE to assure itself that such acceptable level of quality is being maintained at all times. 8.2 Prior to any sale or commercial use, an example of each graphic design incorporating the LICENSED MARKS shall be provided to MIT for its approval and MIT shall have fourteen (14) days from receipt thereof in which to approve in writing said graphic design. Failure to approve shall be deemed as rejection thereof for that graphic design.

 

8.3 All packaging and advertising bearing the LICENSED MARKS shall be subject to the approval of MIT LICENSEE shall furnish to MIT one (1) copy of any packaging and advertisement of LICENSED PRODUCT used by LICENSEE. MIT shall have fourteen (14) days from receipt thereof in which to approve in writing the packaging or advertising materials. In the absence of approval, the packaging and advertising materials shall be deemed as rejected. LICENSEE shall furnish to MIT a further sample of packaging and advertising if it desires to change the packaging or advertising. MIT shall have fourteen (14) days to approve such changed packaging and advertising.

 

8.4 MIT's failure to approve under Paragraphs 8.1, 8.2 and 8.3 above shall be deemed rejection, unless MIT shall have requested within any such fourteen (14) day period an additional period of time (no greater than two (2) additional weeks) for further consideration of the material in question, in which case the initial period for MIT consideration and approval shall be extended by such additional period of time. MIT reserves the right to revise its quality and design criteria at any time and to rereview, pursuant to this Article 8, LICENSEE's merchandise and graphic designs for compliance with such criteria. 8.5 Graphic designs of LICENSED MARKS must conform to the MIT Merchandise Style Guide attached hereto as Appendix D, which can be changed at MIT’s reasonable discretion upon ninety (90) days notice.

 

9. MARKING

LICENSEE agrees that it shall mark the LICENSED PRODUCTS to indicate the rights of MIT in the LICENSED MARKS, including registration status of the LICENSED MARKS and that the products are manufactured pursuant to license. The LICENSED PRODUCTS or their packaging may also bear the statement "made by/for LICENSEE under license from the Massachusetts Institute of Technology, all rights reserved", and each LICENSED PRODUCT shall bear the notation " (R) " if registered for that class of goods or, if not registered for such class of goods, "TM" or other appropriate indication.  Registrations are indicated in Appendix A.

 

10. INDEMNIFICATION AND INSURANCE

10.1 LICENSEE agrees that it is wholly responsible for all products manufactured or SOLD by or for it, including all LICENSED PRODUCTS, and that MIT shall have no liability for any items, including any LICENSED PRODUCT, manufactured or SOLD by or for LICENSEE. LICENSEE shall comply with all government regulations in the manufacture, advertisement, sale, or disposal of the LICENSED PRODUCTS.

 

10.2 LICENSEE shall indemnify, defend, and hold harmless MIT and its trustees, officers, faculty, students, employees, and agents and their respective successors, heirs and assigns (the "Indemnitees"), against any liability, damage, loss, or expense (including reasonable attorneys fees and expenses) incurred by or imposed upon any of the Indemnitees in connection with any claims, suits, actions, demands or judgments arising out of any theory of liability (including without limitation actions in the form of tort, warranty, or strict liability and regardless of whether such action has any factual basis) concerning the use of any LICENSED MARK, or use, sale, manufacture, workmanship, material, design, or advertisement of any LICENSED PRODUCT, arising out of, directly or indirectly, the rights granted in this Agreement.

 

10.3 LICENSEE shall obtain and carry in full force and effect commercial general liability insurance, including product liability insurance, which shall protect LICENSEE and Indemnitees with respect to events covered by Paragraph 10.2 above. Such insurance (i) shall be issued by an insurer licensed to practice in the Commonwealth of Massachusetts or an insurer pre-approved by MIT, such approval not to be unreasonably withheld, (ii) shall list MIT as an additional insured thereunder, (iii) shall be endorsed to include product liability coverage, and (iv) shall require thirty (30) days written notice to be given to MIT prior to any cancellation or material change thereof.

 

The limits of such insurance shall not be less than One Million Dollars ($1,000,000) per occurrence with an aggregate of Two Million Dollars ($2,000,000) for bodily injury including death; and One Million Dollars ($1,000,000) per occurrence with an aggregate of Two Million Dollars ($2,000,000) for property damage. LICENSEE shall provide MIT with Certificates of Insurance evidencing compliance with this paragraph. 

 

LICENSEE shall continue to maintain such insurance after the expiration or termination of this Agreement during any period in which LICENSEE continues to make, have made, or SELL a LICENSED PRODUCT under this Agreement.

 

11. ASSIGNMENT

This Agreement is personal to LICENSEE and may not be assigned without the prior written consent of MIT, which shall not be unreasonably withheld, and the assignee or transferee must agree in writing to MIT to be bound by the terms and conditions of this Agreement prior to such assignment or transfer.

 

12. PAYMENTS, NOTICES AND OTHER COMMUNICATIONS

12.1 Any notices required or permitted under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be sent by hand, recognized national overnight courier, confirmed facsimile transmission, confirmed electronic mail, or registered or certified mail, postage prepaid, return receipt requested, to the following addresses or facsimile numbers of the parties:

 

All notices under this Agreement shall be deemed delivered when sent via confirmed electronic mail, or telecopier to the telefacsimile number identified above, or three (3) days after mailing via certified or registered mail, return receipt requested, postage prepaid, addressed to the party for whom intended, or when actually received by the party for whom intended, whichever is earlier. A party may change its contact information immediately upon written notice to the other party in the manner provided in this paragraph.

 

12.2 Any items (or packages thereof) to be shipped by LICENSEE to MIT shall be deemed sufficiently made or given on the date of receipt by MIT if such package or items are shipped prepaid via Federal Express, UPS, DHL or similar first class service to MIT at the address in Paragraph 12.1.

 

13. MISCELLANEOUS PROVISIONS

13.1 This Agreement shall be construed, governed, interpreted and applied in accordance with the internal laws of the Commonwealth of Massachusetts, U.S.A.

 

13.2 The parties hereto acknowledge that this Agreement sets forth the entire Agreement and understanding of the parties hereto as to the subject matter hereof, and shall not be subject to any change or modification except by the execution of a written instrument executed by the parties hereto.

 

13.3 The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any controlling body of law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the remaining provisions hereof.

 

13.4 The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party.

 

IN WITNESS WHEREOF, the parties have caused this agreement to be executed by their duly authorized representatives.

 

KASAN_국제계약, 영문계약 상표사용허락 라이선스 계약서 샘플 – MIT 대학 로고 상표라이선스 계약서.pdf

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.06.13 16:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

TRADEMARK LICENSE AGREEMENT

 

THIS AGREEMENT is entered into the last date written below by and between [INSERT NAME OF LICENSOR, ENTITY TYPE, and ADDRESS] (“LICENSOR”), and [INSERT NAME OF LICENSEE, ENTITY TYPE, and ADDRESS] (“LICENSEE”).

 

WHEREAS, LICENSOR is the sole and exclusive owner of the following trademarks and registrations: [INSERT] (the “Trademarks”); and

 

WHEREAS, LICENSOR has the power and authority to grant to LICENSEE the right, privilege and license to use the Trademarks on or in association with the goods and/or services covered by the registrations (the “Licensed Products”); and

 

WHEREAS, LICENSEE has represented that it has the ability to manufacture, market and distribute the Licensed Products in [INSERT TERRITORY] (the "Territory") and to use the Trademarks on or in association with the Licensed Products; and

 

WHEREAS, LICENSEE desires to obtain from LICENSOR a license to use, manufacture, have manufactured and sell Licensed Products in the Territory and to use the Trademarks on or in association with the Licensed Products; and

 

WHEREAS, both LICENSEE and LICENSOR are in agreement with respect to the terms and conditions upon which LICENSEE shall use the Trademarks;

 

NOW, THEREFORE, in consideration of the promises and agreements set forth herein, the parties, each intending to be legally bound hereby, do promise and agree as follows.

 

1.  LICENSE GRANT

A.  LICENSOR hereby grants to LICENSEE a non-exclusive license to use the Trademarks on or in association with the Licensed Products in the [INSERT TERRITORY] (Territory), as well as on packaging, promotional and advertising material associated therewith. 

 

B.  LICENSOR hereby grants to LICENSEE the non-exclusive right and license to use, manufacture, have manufactured, sell, distribute, and advertise the Licensed Products in the Territory.  It is understood and agreed that this license shall pertain only to the Trademarks and the Licensed Products and does not extend to any other mark, product or service.

 

C.  LICENSEE may not grant any sublicenses to any third party without the prior express written consent of the LICENSOR which may be withheld for any reason.

 

2.  TERM OF THE AGREEMENT

This Agreement and the provisions hereof, except as otherwise provided, shall be in full force and effect commencing on the last the date of execution below and shall extend for [INSERT LENGTH OF TERM] (the “Term”).

 

3.  COMPENSATION

A.  In consideration for the licenses granted hereunder, LICENSEE agrees to pay to LICENSOR a royalty of ____% (the “Royalty”) based on LICENSEE’s Net Sales of Licensed Products, accruing upon the sale of the Licensed Products (i.e., when the Licensed Product is billed, invoiced, shipped, or paid for, whichever is first regardless of the time of collection by LICENSEE), calculated on a quarterly calendar basis (the "Royalty Period") and shall be payable no later than thirty (30) days after the termination of the preceding full calendar quarter, i.e., commencing on the first (1st) day of January, April, July, and October, with late payments incurring interest at the rate of ONE PERCENT (1%) per month from the date such payments were originally due.

 

B.  In the event that LICENSEE grants any previously approved sub-licenses for the use of the Trademarks in countries outside of the United States, LICENSEE shall pay LICENSOR FIFTY PERCENT (50%) of the gross income received by LICENSEE from such sub-licensees.

 

C.  LICENSEE shall provide LICENSOR with a written royalty statement in a form acceptable to LICENSOR each Royalty Period whether or not any Licensed Products were sold during that Period and the receipt or acceptance by LICENSOR of any royalty statement or payment shall not prevent LICENSOR from subsequently challenging the validity or accuracy of such statement or payment.

 

D.  "Net Sales" shall mean LICENSEE's gross sales (the gross invoice amount billed customers) of Licensed Products, less discounts and allowances actually shown on the invoice and less any bona fide returns.  No other costs incurred in the manufacturing, selling, advertising, and distribution of the Licensed Products or any uncollectible accounts or allowances shall be deducted.   

          

4.  AUDIT

A.  LICENSOR shall have the right, upon at least five (5) days written notice to inspect LICENSEE's books and records and all other documents and material in the possession of or under the control of LICENSEE with respect to the subject matter of this Agreement at a location in the United States.  LICENSOR shall have free and full access thereto for such purposes and shall be permitted to make copies thereof and extracts therefrom.

 

B.  In the event that such inspection reveals a discrepancy in the amount of Royalty owed LICENSOR from what was actually paid, LICENSEE shall pay such discrepancy, plus interest, calculated at the rate of ONE AND ONE-HALF PERCENT (1 1/2%) per month.  In the event that such discrepancy is in excess of ONE THOUSAND UNITED STATES DOLLARS ($1,000.00), LICENSEE shall also reimburse LICENSOR for the cost of such inspection including any attorney's fees incurred in connection therewith.

 

C.  All books and records relative to LICENSEE's obligations hereunder shall be maintained and kept accessible and available to LICENSOR for inspection in the United States for at least three (3) years after termination of this Agreement.

 

D.  In the event that an investigation of LICENSEE's books and records is made, certain confidential and proprietary business information of LICENSEE may necessarily be made available to the person or persons conducting such investigation.  It is agreed that such confidential and proprietary business information shall be retained in confidence by LICENSOR and shall not be used by LICENSOR or disclosed to any third party for a period of two (2) years from the date of disclosure, or without the prior express written permission of LICENSEE unless required by law.  It is understood and agreed, however, that such information may be used in any proceeding based on LICENSEE's failure to pay its actual Royalty obligation.

 

5.  WARRANTIES AND OBLIGATIONS

A.  LICENSOR represents and warrants that it has the right and power to grant the licenses granted herein and that there are no other agreements with any other party in conflict herewith.

 

B.  LICENSOR further represents and warrants that to the best of its knowledge, the Trademarks do not infringe any valid right of any third party.

 

C.  LICENSEE represents and warrants that it will use its best efforts to promote, market, sell, and distribute the Licensed Products.

 

D.  LICENSEE shall be solely responsible for the manufacture, production, sale, and distribution of the Licensed Products and will bear all related costs associated therewith.

 

E.  It is the intention of the parties that LICENSEE shall introduce the Licensed Products in all countries in the Territory on or before [INSERT DATE].  Failure to meet this deadline shall constitute grounds for immediate termination of this Agreement by LICENSOR.

 

6.  NOTICES, QUALITY CONTROL AND SAMPLES

A.  The licenses granted hereunder are conditioned upon LICENSEE's full and complete compliance with the marking provisions of the patent, trademark and copyright laws of the United States and other countries in the Territory.

 

B.  The Licensed Products, as well as all promotional, packaging, and advertising material relative thereto, shall include all appropriate legal notices as required by LICENSOR.  [INSERT REQUIRED NOTICE].

          

C.  The Licensed Products shall be of a high quality which is at least equal to comparable products previously manufactured and marketed by LICENSEE under the trademarks and in conformity with a standard sample approved by LICENSOR.

          

D.  If the quality of a class of the Licensed Products falls below such a production-run quality, as previously approved by LICENSOR, LICENSEE shall use its best efforts to restore such quality.  In the event that LICENSEE has not taken appropriate steps to restore such quality within thirty (30) days after notification by LICENSOR, LICENSOR shall have the right to terminate this Agreement and require that the LICENSEE cease using the Trademarks.

 

E. Prior to the commencement of manufacture and sale of the Licensed Products, LICENSEE shall submit to LICENSOR, at no cost to LICENSOR and for approval as to quality, six (6) sets of samples of all Licensed Products which LICENSEE intends to manufacture and sell and one (1) complete set of all promotional and advertising material associated therewith. Failure of LICENSOR to approve such samples within thirty (30) working days after receipt thereof will be deemed approval.  Once such samples have been approved by LICENSOR, LICENSEE shall not materially depart therefrom without LICENSOR's prior express written consent, which shall not be unreasonably withheld. 

 

F.  At least once during each calendar year, LICENSEE shall submit to LICENSOR, for approval, an additional six (6) sets of samples. 

 

G.  The LICENSEE agrees to permit LICENSOR or its representative to inspect the facilities where the Licensed Products are being manufactured and packaged. 

 

7.  NOTICE AND PAYMENT

A.  Any notice required to be given pursuant to this Agreement shall be in writing and delivered personally to the other designated party at the above stated address or mailed by certified or registered mail, return receipt requested or delivered by a recognized national overnight courier service, except e-mail may be used for day-to-day operations and contacts but not for ‘notice’ or other communications required under this agreement or by law.

 

B.  Either party may change the address to which notice or payment is to be sent by written notice to the other in accordance with the provisions of this paragraph.

 

8.  PATENTS, TRADEMARKS AND COPYRIGHTS

A.  LICENSOR shall seek, obtain and, during the Term of this Agreement, maintain in its own name and at its own expense, appropriate protection for the Trademarks, and LICENSOR shall retain all right, title and interest in the Trademarks as well as any modifications made to the Trademarks by LICENSEE.  LICENSEE agrees that its use of the Trademarks inures to the benefit of LICENSOR and that the LICENSEE shall not acquire any rights in the Trademarks.

 

B.  The parties agree to execute any documents reasonably requested by the other party to effect any of the above provisions.

 

C.  LICENSEE acknowledges LICENSOR's exclusive rights in the Trademarks and, further, acknowledges that the Trademarks are unique and original to LICENSOR and that LICENSOR is the owner thereof.  LICENSEE shall not, at any time during or after the effective Term of the Agreement dispute or contest, directly or indirectly, LICENSOR's exclusive right and title to the Trademarks or the validity thereof.  LICENSOR, however, makes no representation or warranty with respect to the validity of any patent, trademark or copyright which may issue or be granted therefrom.

 

9.  TERMINATION OR EXPIRATION

A.        In addition to the termination rights that may be provided elsewhere in this Agreement, either party may terminate this Agreement upon thirty (30) days written notice to the other party in the event of a breach of a material provision of this Agreement by the other party, provided that, during the thirty (30) day period, the breaching party fails to cure such breach.  Upon expiration or termination, all Royalty obligations, including any unpaid portions of the Guaranteed Minimum Royalty, shall be accelerated and shall immediately become due and payable, and LICENSEE's obligations for the payment of a Royalty and the Guaranteed Minimum Royalty shall survive expiration or termination of this Agreement and will continue for so long as LICENSEE continues to manufacture, sell or otherwise market the Licensed Products.

 

B.        Upon expiration or termination, LICENSEE shall provide LICENSOR with a complete schedule of all inventory of Licensed Products then on-hand (the "Inventory").

 

C.  Upon expiration or termination, except for reason of a breach of LICENSEE's duty to comply with the quality control or legal notice marking requirements, LICENSEE shall be entitled, for an additional period of three (3) months and on a nonexclusive basis, to continue to sell such Inventory.  Such sales shall be made subject to all of the provisions of this Agreement and to an accounting for and the payment of a Royalty thereon, due and paid within thirty (30) days after the close of the three (3) month period.

 

D.  Upon the expiration or termination of this Agreement, all of the rights of LICENSEE under this Agreement shall terminate and immediately revert to LICENSOR and LICENSEE shall immediately discontinue all use of the Trademarks at no cost whatsoever to LICENSOR, and LICENSEE shall immediately return to LICENSOR all material relating to the Trademarks including at no cost to LICENSOR.

          

10.  GOOD WILL

LICENSEE recognizes the value of the good will associated with the Trademarks and acknowledges that the Trademarks and all rights therein including the good will pertaining thereto, belong exclusively to LICENSOR. 

 

11.  INFRINGEMENTS

If an action for infringement of the rights licensed in this Agreement is brought, each party shall execute all papers, testify on all matters, and otherwise cooperate in every way necessary and desirable for the prosecution of any such lawsuit.

 

12.  INDEMNITY

LICENSEE agrees to defend and indemnify LICENSOR, its officers, directors, agents and employees, against all costs, expenses and losses (including reasonable attorneys' fees and costs) incurred through claims of third parties against LICENSOR based on the manufacture or sale of the Licensed Products including, but not limited to, actions founded on product liability. 

 

13.  INSURANCE

LICENSEE shall, throughout the Term of the Agreement, obtain and maintain at its own cost and expense from a qualified insurance company licensed to do business in California, standard Product Liability Insurance naming LICENSOR as an additional named insured.  Such policy shall provide protection against any and all claims, demands and causes of action arising out of any defects or failure to perform, alleged or otherwise, of the Licensed Products or any material used in connection therewith or any use thereof.  The amount of coverage shall be a $10 million combined single limit for each single occurrence for bodily image and/or property damage.  The policy shall provide for ten (10) days notice to LICENSOR from the insurer by Registered or Certified Mail, return receipt requested, in the event of any modification, cancellation or termination thereof.  LICENSEE agrees to furnish LICENSOR a certificate of insurance evidencing same within thirty (30) days after execution of this Agreement and, in no event shall LICENSEE manufacture, distribute or sell the Licensed Products prior to receipt by LICENSOR of such evidence of insurance.

 

14.  JURISDICTION AND DISPUTES

A.  This Agreement shall be governed in accordance with the laws of the State of California, United States of America.

 

B.  Any controversy, claim or dispute arising out of or relating to this Agreement or the breach, termination, enforcement, interpretation or validity thereof, including the determination of the scope or applicability of this agreement to arbitrate (except at the option of either party for any application for injunctive relief) shall be finally settled by arbitration in Los Angeles County, California under the rules of the American Arbitration Association (AAA) before one arbitrator and judgment upon the award rendered may be entered in any court having jurisdiction.  In this regard, the parties submit to the personal subject matter jurisdiction of the State of California.  The arbitration provisions of this Section shall be interpreted according to, and governed by, the Federal Arbitration Act, and any action to enforce any rights hereunder shall be brought exclusively in the U.S. District Court for the Central District of California.  EACH PARTY HERETO KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES ANY RIGHT TO A TRIAL BY JURY OF ANY DISPUTE RELATING TO THIS AGREEMENT AND AGREES THAT ANY SUCH ACTION SHALL BE ADJUDICATED BY AN ARBITRATOR AND WITHOUT A JURY.

 

C.  The parties may mutually agree upon any procedure for appointing the arbitrator and shall inform the AAA administrator as to such procedure; however, if within 45 days after the commencement of the arbitration, all of the parties have not mutually agreed on a procedure for appointing the arbitrator or have not mutually agreed on the designation of the arbitrator, the AAA administrator shall unilaterally appoint and designate the presiding arbitrator.

 

D.  If a party fails to file a statement of defense within the time established by the tribunal without showing sufficient cause for such failure, as determined by the tribunal, or if a party, duly notified, fails to appear at a hearing without showing sufficient cause for such failure, as determined by the tribunal, the tribunal may proceed with the arbitration; or if a party, duly invited to produce evidence or take any other steps in the proceedings fails to do so within the time established by the tribunal without showing sufficient cause for such failure, as determined by the tribunal, the tribunal may make the award on the evidence before it.

 

E.  The arbitrator may, in the Award, allocate all or part of the costs of the arbitration, including the fees of the arbitrator and the reasonable attorneys’ fees of the prevailing party.

 

15.  AGREEMENT BINDING ON SUCCESSORS

The provisions of this Agreement shall be binding on and shall inure to the benefit of the parties hereto, and their heirs, administrators, successors, and assigns.

 

16.  WAIVER

No waiver by either party of any default shall be deemed as a waiver of prior or subsequent default of the same or other provisions of this Agreement.

 

17.  SEVERABILITY

If any term, clause, or provision hereof is held invalid or unenforceable by a court of competent jurisdiction, such invalidity shall not affect the validity or operation of any other term, clause or provision and such invalid term, clause or provision shall be deemed to be severed from the Agreement.

 

18.  NO JOINT VENTURE

Nothing contained herein shall constitute this arrangement to be employment, a joint venture or a partnership.

 

19.  ASSIGNABILITY

The license granted hereunder is personal to LICENSEE and shall not be assigned by any act of LICENSEE or by operation of law unless in connection with a transfer of substantially all of the assets of LICENSEE or with the consent of LICENSOR.

 

20.  GOVERNMENTAL APPROVAL

As promptly as possible after execution of this Agreement, LICENSEE agrees to submit copies of this Agreement to any governmental agency in any country in the Territory where approval of a license agreement is necessary and agrees to promptly prosecute any such application diligently.  This Agreement shall only become effective in such country or countries upon receipt of appropriate approval from the applicable governmental agency.

 

21.  INTEGRATION

This Agreement constitutes the entire understanding of the parties, and revokes and supersedes all prior agreements between the parties, including any option agreements which may have been entered into between the parties, and is intended as a final expression of their Agreement.  It shall not be modified or amended except in writing signed by the parties hereto and specifically referring to this Agreement.  This Agreement shall take precedence over any other documents which may be in conflict with said Agreement.

 

22.  AMENDMENTS

Any amendment to this Agreement must be in writing and signed by an authorized person of each party.

 

 

 

 

IN WITNESS WHEREOF, the parties hereto, intending to be legally bound hereby, have each caused to be affixed hereto its or his/her hand and seal the day indicated.

 

[INSERT NAME OF LICENSOR]  [INSERT NAME OF LICENSEE]

 

By:                                                         By: 

Title:                                              Title: 

Date:                                            Date: 

 

KASAN_국제계약, 영문계약 실무 - 상표사용허락 라이선스 계약서 조항 샘플.pdf

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.06.13 08:27
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

A covenant is a promise by a party by which it pledges that something is either done, will be done or shall not be done.

      Example 1: “Licensee shall pay Licensor a flat royalty based on 2.5% of Gross Revenues received from the sale of Licensed Products.”

      Example 2: “Company A hereby covenants not to sue Company B under any patent listed in Exhibit A for infringement based upon any act by Company B of manufacture, use, sale, offer for sale or import that occurs after the Effective Date.”

 

A representation is a statement of fact that induces a party to enter into the contract. The statement, made before or at the time of making the contract, regards a past fact or existing circumstance related to the contract which influences such party to enter the contract.

      Example 1: “Licensor represents to Licensee that it has the full and unencumbered right, power and authority to enter into this Agreement and to grant the license rights granted by Licensor to Licensee hereunder.

      Example 2: “Company A hereby represents that it owns full legal and equitable title to each patent listed in Exhibit A.”

 

A warranty is an undertaking or stipulation that a certain fact in relation to the subject of the contract is or shall be as it is stated or promised; and refers to an agreement to protect the recipient against loss if the fact is or becomes untrue (i.e., an implied indemnification).

      Example 1: “Licensor warrants to Licensee that it has not received any written notice or claim, and is not otherwise aware that the Licensed Technology infringes or misappropriates the proprietary rights of any other Person.”

      Example 2: “Company A warrants to Company B that the Technical Information provided hereunder will be the same as that used in the design, production, installation, and maintenance of Licensed Products produced in its own factories.”

 

A claim for breach of a covenant may be for damages or specific performance. When a breach of a covenant is “material” (i.e., a breach that destroys the value of the contract for the non-breaching party), however, it excuses the non-breaching party’s performance.  This often is subjective and can be expensive to prove in later litigation. (Thus, the more specificity drafted into a contract – i.e., a listing of the specific and most-likely events that trigger a termination event – the better that contract protects the parties.)

 

Upon a false representation (or misrepresentation), however, the defrauded party may elect to void the entire contract and recover any sums paid.

 

When a breach of warranty occurs, the damages recoverable are the difference in the value as warranted (i.e., how they should have been) and the value as received.

 

This is because “representations” should be statements made by a party after investigation and with a belief that such statements are true, and “warranties” should be statements a party makes while willing to accept financial responsibility if the statement turns out to be untrue, regardless of whether they actually (or should have) investigated.

 

In sum, upon a breach of a covenant or breach of warranty, the contract remains binding and damages only are recoverable for the breach; whereas, upon a misrepresentation, the defrauded party may elect to void the entire contract. 

 

KASAN_기술이전, 라이선스, 특허실시, 공동연구개발 국제계약, 영문계약 실무상 기본용어 설명 참고자료 – cov

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.06.10 11:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

Taxes; Withholding.

Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the efforts of the Parties under this Agreement. 

 

In the event that any payment under this Agreement becomes subject to withholding taxes, other than income tax, under Applicable Laws, the payor may withhold from the payment the amount of such taxes due. 

 

Payor will timely pay to the proper governmental authority the amount of any taxes withheld and will provide the payee with an official tax certificate or other evidence of tax obligation together with proof of payment from the relevant governmental authority sufficient to enable payee to claim such payment of taxes. 

 

The Parties agree to cooperate with one another and use reasonable efforts to minimize or eliminate such tax withholding or similar obligations in respect of royalties, milestone payments, and any other payments made by Licensee to Licensor under this Agreement.  The Parties shall, wherever possible, endeavour and cooperate to minimize the taxes due under this Agreement.   

 

Records; Audits. 

Licensee and its Affiliates will maintain, and Licensee will cause each of its Sublicensees, if any, to maintain, complete and accurate records in sufficient detail to confirm the accuracy of the calculation of royalty payments and the achievement of milestone events, for a period of three (3) years after the Calendar Year in which such sales or events occurred or for the period required under the Applicable Laws, whichever is longer. 

 

Upon reasonable prior notice and without disruption to Licensee’s business, such records of Licensee and its Affiliates and Sublicensees shall be made available during regular business hours for a period of three (3) years from the end of the Calendar Year to which they pertain for examination, and not more often than once each Calendar Year, by an independent certified public accountant among the major internationally reputable accounting firms selected by Licensor, for the sole purpose of and only to the extent necessary for verifying the accuracy of the financial reports furnished by Licensee pursuant to this Article 8. 

 

Such independent accountant shall disclose to Licensor only the amounts that such independent accountant believes to be due and payable hereunder to Licensor, details concerning any discrepancy from the amount paid and the amount due, and shall disclose no other information revealed in such audit. 

 

Any and all records examined by such independent accountant shall be deemed Licensee’s Confidential Information which may not be disclosed by such independent accountant to any Third Party, and Licensee may require such independent accountant to enter into an appropriate written agreement obligating it to be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less protective than those set forth in Article 16. 

 

If, as a result of any inspection of the books and records of Licensee, it is shown that payments under this Agreement were less than the amount which should have been paid, then Licensee shall make all payments required to be made plus interest (as set forth in Section 8.7) from the original due date to eliminate any discrepancy revealed by such inspection within thirty (30) days. 

 

If, as a result of any inspection of the books and records of Licensee, it is shown that payments under this Agreement were more than the amount which should have been paid, then Licensor shall, at Licensee’s election, either make all payments required to be made to eliminate any discrepancy revealed by such inspection within ninety (90) days or credit such amounts to Licensee against future payments. 

 

Licensor shall pay for such audits, except that in the event that the audited amounts were underpaid by Licensee by more than five percent (5%) of the undisputed amounts that should have been paid during the period in question as per the audit, Licensee all pay the costs of the audit.

 

KASAN_기술이전, 라이선스, 특허실시, 공동연구개발 국제계약서, 영문계약서에서 TAX 세무조항, RECORD,

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.06.10 09:16
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

 

KASAN_독점라이선스 국제계약서에서 계약종료 시 라이센시의 보상청구 관련 주요내용, 분쟁사례, 판결 및 중재판정

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.06.05 17:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

4.1. Compliance with Legal Requirements.

Licensee shall conduct, and shall ensure that its Affiliates, Sublicensees and Subcontractors, conduct, all activities hereunder, including all Development and Commercialization of the Product, in compliance with all Applicable Laws.

 

In addition, Licensee hereby certifies that (i) to its reasonably knowledge or belief, neither Licensee nor its Affiliates has been, prior to the Effective Date debarred under United States law, including Section 21 U.S.C. 335a (or any foreign equivalent thereof), and (ii) neither Licensee nor its Affiliates will, from and after the Effective Date, employ or otherwise use in any capacity, the services of any Person, who to the knowledge or belief of Licensee or any of its Affiliates is, debarred under United States law, including Section 21 U.S.C. 335a (or any foreign equivalent thereof) to perform any portion of the activities hereunder, including any Development and Commercialization of the Product.

 

Licensee shall notify Sub-Licensor in writing promptly upon becoming aware of any such debarment of any such Person, and shall, upon becoming so aware, promptly remove such Person from performing any such activities and from any function or capacity related to any such activities.

 

4.2. Compliance with Ethical Business Practices.

(a) Compliance with Laws and Policies.

Licensee shall conduct the activities contemplated herein, and shall ensure that its Affiliates, Sublicensees and Subcontractors, conduct the activities contemplated herein, in a manner which is consistent with all Applicable Laws in Korea including, as applicable, Good Clinical Practices, Good Laboratory Practices, the U.S. Foreign Corrupt Practices Act which generally prohibits the promise, payment or giving of anything of value either directly or indirectly to any Official for the purpose of obtaining or retaining business or any improper advantage, and the UK Bribery Act of 2010 which additionally includes the prohibition on the making of any bribe to a foreign public official with the intention of influencing such person in order to obtain or retain business or an advantage in the conduct of business, and good business ethics.

 

(b) Governments and International Public Organizations.

Licensee warrants that, in connection with this Agreement and Licensee’s business relating thereto, Licensee, its directors, employees, officers, and anyone acting on Licensee’s behalf or with Licensee’s knowledge, shall not offer, make or promise any payment, and shall ensure that its Affiliates, Sublicensees and Subcontractors, do not offer, make or promise any payment (either directly or indirectly, of money or other assets) to any government officials (including any government-owned or controlled commercial enterprise), or political party officials, officials of international public organizations, candidates for public office, or representatives of other businesses or persons acting on behalf of any of the foregoing (hereinafter collectively referred as “Officials”) where such payment (either directly or indirectly of money or other assets) would constitute a violation of any Applicable Law.

 

In addition, Licensee shall make no payment (either directly or indirectly of money or other assets), and shall ensure that its Affiliates, Sublicensees and Subcontractors, make no payment in connection with this Agreement or Licensee’s business relating thereto, either directly or indirectly to Officials if such payment (either directly or indirectly of money or other assets) is for the purpose of (i) influencing decisions or actions with respect to the subject matter of this Agreement or any other aspect of either Party’s business; (ii) inducing such Official to do or omit to do any action in violation of the lawful duty of such Official; (iii) securing any improper advantage; or (iv) inducing such Official to use his/her position to affect or influence any decisions or actions of government or any legislative, administrative, public agency or other public body with respect to any activities undertaken relating to this Agreement.

 

Additionally, Licensee will make reasonable efforts to comply with requests for information, including answering questionnaires and narrowly tailored audit inquiries, to the extent they relate to the subject of this Agreement, to enable Licensor to ensure compliance with any applicable anti-corruption laws.

 

(c) Disclosure.

Where Licensor requests reasonable information regarding disclosure of any officers, employees, owners, or persons directly or indirectly retained by Licensee who are Officials or relatives of Officials of any governmental authority with oversight over the performance of Licensee’s obligations under this Agreement or any Regulatory Documentation, if such persons are engaged to perform Licensee’s obligations under this Agreement, Licensee shall provide complete and accurate information and documentation to Licensor with respect thereto. Licensee shall update such disclosures upon request of Licensor from time to time as necessary to ensure the information provided remains complete and accurate for the Term of this Agreement.

 

(d) Books and Records.

Licensee represents, warrants and covenants that all books, records, invoices and other documents relating to payments and expenses under this Agreement are and shall be complete and accurate and reflect in reasonable detail the character and amount of transactions and expenditures. Licensee further represents, warrants and agrees that no “off the books” or similar funds will be maintained or used in connection with this Agreement.

 

(e) Compliance Training.

Licensee agrees to ensure that all of Licensee’s employees involved in performing the obligations under this Agreement are made specifically aware of the compliance requirements under Sections 4.2(a), (b), (d), (e) and (f).

 

(f) Exclusions Lists.

Licensee shall not use (and shall cause its Affiliates not to use) any Person (including any employee, officer, director, Sublicensee or Third Party contractor) who is (or has been) on the Exclusions List, or who is (or has been) in Violation, in the performance of any activities hereunder. Licensee certifies to Sub-Licensor that as of the Effective Date, Licensee has screened itself, and its officers and directors (and its Affiliates, Sublicensees and Third Party contractors and their respective officers and directors) against the Exclusions Lists and that it has informed Licensor whether Licensee, or any of its officers or directors (or any of its Affiliates, Sublicensees or Third Party contractors or any of their respective officers and directors) has been in Violation. After the Effective Date, Licensee shall notify Licensor in writing immediately if any such Violation occurs or comes to its attention.

 

(g) Obligation to Notify.

Licensee shall promptly notify Licensor upon becoming aware of any violation of any anti-corruption laws by Licensee or its Affiliate or those acting on Licensee’s behalf in connection with the matters that are the subject of this Agreement and the performance by Licensee of its obligations hereunder.

 

(h) Compliance Audits.

Licensee shall maintain books and records that are complete and accurate in all material respects relating to its compliance by Licensee and its Affiliates that is engaged in carrying out activities in connection with this Agreement with anti-corruption laws and with respect to its obligations under this Agreement (collectively, the “Compliance Records”) for a period of two (2) years after the period to which such records relate or such longer period as required by Applicable Laws, which Compliance Records shall include: (a) its policies and procedures including those of Licensee and its Affiliates concerning compliance with anti-corruption laws with respect to its obligations under this Agreement, (b) records of any investigations and remedial and disciplinary actions undertaken to address material violations of anti-corruption laws with respect to its obligations under this Agreement and (c) records of any payments made by it or Licensee and its Affiliates in connection with this Agreement. Upon reasonable advance written notice to Licensee, Licensor shall be entitled, at its cost and expense, to have access to and audit the Compliance Records of Licensee and any of its Affiliates (to the extent such Compliance Records are not subject to attorney-client privilege) for a period of two (2) years after the period to which such records relate or such longer period as required by applicable anti-corruption laws. Licensor may not exercise this audit right more frequently than once during any twelve (12)-month period; provided, however, that if any audit by Licensor under this Section 4.2(h) reveals that Licensee or any of its Affiliates is or was not in material compliance with applicable anti-corruption laws in relation to the performance of its obligations under this Agreement, Licensor shall have the right to conduct such additional audits (for clarity, such additional audits shall apply only to the applicable Licensee and its Affiliates which was so determined during the initial audit in such twelve (12)-month period to not be in material compliance) during such twelve (12)-month period as may be reasonably required to determine whether Sub-Licensee and its Affiliates have appropriately remedied such non-compliance.

 

4.3. Termination for Non-Compliance.

Any uncured violation by Licensee or any of its Affiliates of any applicable anti-corruption laws in connection with its obligations under this Agreement shall be a material breach of this Agreement entitling Sub-Licensor to terminate this Agreement pursuant to Section 11.2(c).

 

4.4. Responsibility for Compliance.

Licensee acknowledges and agrees that neither Licensor, nor or any of its Affiliates or Licensor’s or its Affiliates’ officers, directors, employees, agents and representatives is authorized to waive compliance with the provisions of Section 4.3 and/or to give any direction, either written or oral, relating to the making of any commitment by Licensee or its agents to any Third Party in violation of the terms of this ARTICLE 4, and that Sub-Licensee shall be solely responsible for its compliance with all applicable anti-corruption laws irrespective of any act or omission of Merck or any of Merck’s Affiliates or Merck’s or its Affiliates’ officers, directors, employees, agents and representatives.

 

KASAN_기술이전, 라이선스, 특허실시, 공동연구개발 등 국제계약서, 영문계약서에서 미국법 FCPA, Anti-C

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.06.05 12:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

1 (공정의무)

 1) 양 당사자(그 임직원을 포함)는 본 계약의 체결, 이행 및 유지에 있어 거래의 공정성에 대한 확보가 중요한 전제 조건임을 인식하고, 타방 당사자(그와 동일시 할 수 있는 친인척 등 관계자 포함) 또는 본 계약과 관련한 제3(이하 거래 상대방이라 한다)에 대하여 거래의 공정성을 해할 수 있는 행위(이하 "비위행위라 한다)를 하여서는 아니 된다. "비위행위"의 예는 다음 각 호에 열거되어 있는 바와 같으며, 이에 한하지 아니한다.

금전을 제공하는 행위

사회통념수준을 초과하는 선물 또는 식사를 제공하는 행위

불건전 업소, 오락, 골프, 스키 등의 향응 및 접대를 하는 행위

출장지원, 개인 휴가 지원, 사무실 비품 제공, 협찬/찬조 등의 편의를 제공하는 행위

차용/매입/매도, 부채상환, 보증, 금전대차 등 금전 또는 부동산 관련 모든 거래행위

공동투자 및 공동재산의 취득 기회를 제공하거나, 합작투자 또는 거래 상대방의 회사에 겸직하도록 하는 행위

거래 상대방의 주식이나 기타 관련업체의 주식을 제공 또는 투자하도록 하거나 기타 재산을 공동 투자 또는 취득하도록 하는 행위

고용보장, 취업알선의 약속 등 미래에 대한 보장을 하는 행위

기타 타방 당사자의 정도경영 준수사항을 위반하거나, “거래 상대방이 공정하게 업무를 수행하는 데 지장을 초래하는 행위

 

2) 양 당사자는 거래 공정성 확보를 위해 다음 각 호의 사항을 협조하도록 한다.

타방 당사자의 임직원을 상대로 일방 당사자의 임직원 등에 의해 이루어진 비위행위가 발견되거나 비위행위에 대한 의혹이 있는 경우, 양 당사자는 그와 관련된 자료의 제출 또는 열람을 상대방 당사자에게 요구할 수 있으며, 이 경우 양 당사자는 해당 요구에 적극 협조하여야 한다.

일방 당사자는 타방 당사자의 임직원으로부터 본 조 제1항 각 호의 행위를 제의받거나, 이러한 사실을 인지한 때에는 타방 당사자의 관련 부서에 즉각 신고토록 한다.

양 당사자는 본 계약 외에 상대 당사자의 정도경영 실천에 적극 협조한다.

 

3) 본 조는 본 계약의 종료(만료, 해지 또는 해제 포함) 후에도 유효하다.

 

4) 본 계약의 일방 당사자가 본 조항의 공정의무를 위반한 경우 그 상대방은 본 계약을 즉시 해지할 수 있다.

 

KASAN_기술이전, 라이선스, 특허실시, 공동연구개발 등 국문계약서에서 공정의무, 반부패의무, 비위행위금지, An

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.06.05 11:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

KASAN_국제계약, 영문계약에서 Anti-Corruption, Compliance 쟁점, 미국법 FCPA 관련 주

 

[질문 또는 상담신청 입력하기]

 

 

 

작성일시 : 2019.06.05 09:16
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

17. TERM AND TERMINATION. 

17.1 Termination Prior to the Closing Date.

This Agreement may be terminated at any time prior to the Closing Date (with respect to Sections 17.1(b) and 17.1(c) below, by written notice by the terminating Party to the other Party): (a) by mutual written agreement of the Parties;

 

(b) by Licensor or Licensee, if a court of competent jurisdiction or other Governmental Authority shall have issued a non-appealable final order, decree or ruling or taken any other non-appealable final action, in each case, having the effect of permanently restraining, enjoining or otherwise prohibiting the transactions contemplated by this Agreement; provided, however, that the right to terminate this Agreement under this Section 17.1(b) shall not be available to any Party whose failure to fulfill any obligation under this Agreement has been the primary cause of, or materially contributed to, such action; or

 

(c) by Licensee, if Licensor has breached any representation, warranty, covenant or agreement of Licensor set forth in this Agreement which (i) would result in a failure of a condition set forth in Section 13.2 and (ii) is not cured within thirty (30) calendar days after written notice thereof.   

 

17.2 Term.

Except as provided in Section 17.1, this Agreement shall continue until the date of expiration of the Royalty Term, unless earlier terminated in accordance with this Article 17 (the “Term”).  

 

17.3 Termination of the Agreement After the Closing Date.  

 

(a) Termination by Licensee. 

Licensee may terminate this Agreement in its entirety or in part (including, for example, on a country-by-country basis) for any reason (a) upon at least ninety (90) days prior written notice to Licensor if such notice is delivered prior to the First Commercial Sale of a Licensed Product anywhere in the Territory or (b) upon at least one hundred eighty (180) days prior written notice to Licensor if such notice is delivered after the First Commercial Sale of a Licensed Product anywhere in the Territory.  In the event of any significant adverse clinical events or the termination of a Clinical Trial for safety reasons and Licensee terminates this Agreement under this Section 17.3(a), the foregoing notice periods in clauses (a) and (b) shall be reduced to forty-five (45) days and ninety (90) days, respectively.

 

(b) Termination for Material Breach. 

If either Party believes the other is in material breach of its obligations under this Agreement, it may give notice of such breach to the other Party, which Party shall have sixty (60) days in which to remedy such breach, or thirty (30) days in the case of material breach of any payment obligation hereunder.

 

Such sixty (60) day period shall be extended in the case of a breach not capable of being remedied in such sixty (60) day period so long as the breaching Party uses diligent efforts to remedy such breach and is pursuing a course of action that, if successful, will effect such a remedy; provided, however, that such cure period shall not be extended more than sixty (60) additional days. 

 

If such alleged breach is not remedied or is not capable of being remedied within the period set forth above, the non-breaching Party shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement, and in addition to any other remedies available to it by law or in equity, to terminate this Agreement upon written notice to the other Party.  In the event of a dispute regarding any payments due and owing hereunder, all undisputed amounts shall be paid when due and the balance, if any, shall be paid promptly after settlement of the dispute including any accrued interest thereon.  

 

(c) Consequences of Termination. 

In the event that either Party terminates this Agreement, then as of the effective date of such termination, the following terms and conditions shall apply:

 

(i) Termination by Licensor for Licensee’s Material Breach. 

In the event of termination of this Agreement by Licensor pursuant to Section 17.3(b) for Licensee’s uncured material breach, and except for each Party’s rights and obligations that survive termination as set forth in Section 17.5:

 

(A) all licenses and rights granted by either Party under this Agreement shall terminate with the exception, subject to Section 19.1, of the license granted to Licensor by Licensee under the Licensee Inventions relating to formulations or methods of manufacturing formulations derived from the Licensed Intellectual Property pursuant to Section 9.2(c) which shall become perpetual, worldwide and fully paid; 

 

(B) Licensee shall pay Licensor any and all payments that have accrued prior to the effective date of such termination; 

 

(C) Licensee shall transfer to Licensor all materials, results, analyses, reports, websites, marketing materials, technology, know-how and other Information in whatever form received by Licensee from Licensor as of the effective date of such termination; 

 

(D) Licensee shall transfer to Licensor (A) all Regulatory Approvals in the Territory in effect as of the date of such termination and/or (B) any and all Information pertaining to the Development and Commercialization of the Licensed Products in the Territory, including but not limited to any and all Clinical Trial data pertaining to the Territory. 

 

(ii) Termination by Licensee. 

Subject to Section 17.3(c)(ii)(E), in the event of termination of this Agreement by Licensee pursuant to Section 17.3(a), and except for each Party’s rights and obligations that survive termination as set forth in Section 17.5:  

 

(A) all licenses and rights granted by either Party under this Agreement shall terminate, with the exception, subject to Section 19.1, of the license granted to Licensor by Licensee under the Licensee Inventions relating to formulations or methods of manufacturing formulations derived from the Licensed Intellectual Property pursuant to Section 9.2(c), which shall become worldwide, subject to Licensor’s obligations under subsection (E) below;  

 

(B) Licensee shall pay Licensor any and all payments that have accrued prior to the effective date of such termination; 

 

(C) Licensee shall transfer to Licensor all materials, results, analyses, reports, websites, marketing materials, technology, know-how and other Information in whatever form received by Licensee from Licensor as of the effective date of such termination;  

 

(D) Licensee shall, upon receipt of reasonable consideration from Licensor based on an actual cost basis, transfer to Licensor (A) all Regulatory Approvals in the Territory in effect as of the date of such termination and/or (B) any and all Information pertaining to the Development and Commercialization of the Licensed Products in the Territory, including but not limited to any and all Clinical Trial data pertaining to the Territory; and 

 

(E) in partial consideration for (A) Licensee’s costs of obtaining and maintaining such Regulatory Approvals and Commercializing Licensed Products in the Territory prior to the date of such termination, and/or (B) subject to Section 19.1, the license granted under the Licensee Inventions, Licensor shall pay to Licensee following the effective date of such termination, on a product-by-product and country-by-country basis, a commercially reasonable royalty to be negotiated in good faith by the Parties, on all sales by Licensor, its Affiliates and Sublicensees, of products that would have been Licensed Products, had they been sold by Licensee prior to the effective date of such termination. 

 

(iii) Termination by Licensee for Licensor’s Material Breach.  

In the event that Licensee has the right to terminate this Agreement for Licensor’s uncured material breach pursuant to Section 17.3(b), Licensee may terminate this Agreement or, in lieu of such termination, by written notice to Licensor after a determination that such breach was a material breach and was not cured before the expiration of the cure period set forth in Section 17.3(b), elect to retain all of the rights and licenses granted to Licensee hereunder for the remainder of the Term. Following such an election by Licensee:

 

(A) Licensee may request that damages be awarded to Licensee for Licensor’s uncured material breach by final and binding arbitration conducted in accordance with Section 19.12. In determining whether damages should be awarded to Licensee, the arbitrators shall consider the nature of Licensor’s uncured material breach and the impact of such uncured material breach on Licensee and the transactions contemplated by this Agreement. 

 

In the event that such final and binding arbitration determines that Licensee should be awarded damages, Licensee shall be entitled to deduct the amount of such damages from milestone and royalty payments to be paid to Licensor under Sections 8.2 and 8.3;

 

(B) the limitations applicable to Licensor’s activities as set forth in Sections 2.3(a) and 2.4 shall continue to apply; and

 

(C) the license granted by Licensee to Licensor under Section 9.2(c) shall terminate.    

 

17.4 Surviving Obligations. 

Upon termination of this Agreement, the Parties shall remain obligated to make all payments which have accrued under this Agreement prior to the date of termination, when and as they become due and payable.  In addition, the provisions in Articles 1, 9, 10, 14, 15, 16, 18 and 19, and Sections 2.6, 5.2, 5.7, 7.6, 8.3(h), 8.7 (with respect to payment accruing prior to the effective date of termination), 8.8, 8.9, 17.3(c), 17.4 and 17.5 of this Agreement shall survive termination of this Agreement for any reason.  

 

17.5 Accrued Rights. 

Termination or expiration of this Agreement shall not relieve either Party from obligations that are expressly indicated to survive termination or expiration of the Agreement.  Termination by a Party shall not be an exclusive remedy and all other remedies will be available to the terminating Party, in equity and at law.

 

KASAN_국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 계약종료, 계약해지, TERMIN

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.06.04 13:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

ARTICLE 2 - TECHNICAL ASSISTANCE

2.1   TECHNICAL DOCUMENTATION

           (a) Licensor shall furnish to Licensee, in accordance with the time schedule to be agreed upon between the Parties, one (1) set of hard copies of the Technical Documentation. If Licensee discovers that any of the documents are missing or illegible or damaged, Licensee shall inform Licensor in writing and Licensor shall make such documents available for Licensee within twenty (20) days of receiving such notice.

                                                             

           (b) The foregoing Technical Documentation to be furnished under paragraph 2.1 (a) above shall be delivered to Licensee and shall be the latest version as of the time it is delivered or sent.

 

           (c) Licensee shall pay Licensor for any additional copies of the Technical Documentation requested by Licensee at the rates agreed upon in writing by both Parties prior to sending.

 

           (d) Nothing in this Agreement shall be construed to require that Licensor furnish Licensee with any technical information on any products other than Licensed Product or any technical information which may not be furnished because of a government contract, act, regulation or restriction or the proprietary interest of a third party.

 

           (e) Errors in Technical Documentation. Each Party shall promptly advise the other of any significant error it may discover in the Technical Documentation. In that event, Licensor shall correct any error in the Technical Documentation and shall furnish such corrected Technical Documentation to Licensee without charge.

 

(f) Strict Compliance with Technical Documentation. In order to maintain the quality of the Licensed Products manufactured and assembled by Licensee pursuant to this Agreement, Licensee shall manufacture and/or assemble the Licensed Products in strict accordance with the standards and specifications stated in the Technical Documentation provided by Licensor and as otherwise specified by Licensor. Licensee shall exercise the utmost care in the selection of the materials and parts to be used and incorporated into the Licensed Products.

 

2.2      ASSISTANCE BY LICENSOR

Licensor shall provide reasonable assistance in the use of the Technical Documentation to the extent such assistance is reasonably necessary for Licensee to make use of the Technical Documentation to manufacture the Licensed Product. Such assistance may include, but will not be limited to, technical assistance, training, testing and limited application engineering services.

 

- 라이센서의 조력의무를 선언적으로 규정한 조항임. 제조에 필요한 기술정보 활용을 가능케 하도록 조력의무를 규정하고 있어 상당히 포괄적임.

- 이하에서 구제적인 비용을 규정할 경우 라이센서의 수입원이 되지만, 그렇지 않을 경우 부담조항이 될 수 있음.

                                                                           

2.3   TECHNICAL ASSISTANCE

      (a) At the request of Licensee, Licensor shall, at times agreed upon by the Parties, dispatch its engineers to Licensee to provide technical assistance on matters concerning the use of the Technical Documentation during the Technical Cooperation Period. All costs and expenses of such Licensor's personnel dispatched to Licensee shall be borne, or reimbursed to Licensor, by Licensee and shall include:

            (i)   round trip economic air fare between Korea and China;

            (ii)  suitable accommodations, meals, traveling and transportation expenses in China and other reasonable charges in connection with the performance of their duties hereunder;

            (iii) wage and daily allowance, payable to Licensor, on its demand, amounting to U$500 per Man Day for Licensor's personnel;

 

      (b) Licensee shall take appropriate steps necessary to protect and ensure the safety of Licensor's personnel and their property, including without limitation, against war, war-like operation, terror, revolution, civil commotion, catastrophe and acts of public enemies. Licensor reserves the right to  instruct any or all of its dispatched personnel to return to Korea, or such other place as it may designate, at Licensee's expense  when, in Licensor's sole judgment , one of the above-mentioned situations arises which may endanger the safety and well-being of such personnel.

- 기술자 파견에 따른 안전보장은 실시자 부담임

 

      (c) Licensee is responsible for obtaining any permits or authorizations required for Licensor's personnel to enter China to provide services hereunder, and to bring any related materials required by Licensor.

- 기술자 파견에 따른 출입국 보장은 실시자 부담

 

    (d) The number of such personnel, the period of their stay at Licensee's plant and other terms and conditions not set forth herein shall be agreed upon between the Parties on a case by case basis.

 

2.4   TRAINING

At the request of Licensee, Licensor will, during the Technical Cooperation Period, provide training on the use of the Technical Documentation for Licensee's employees (the "Trainees") at Licensor's place or other places designated by Licensor, subject to the following terms and conditions:

      (i) Licensor and Licensee shall agree on the most efficient training program for the Trainees;

      (ii) Licensee shall bear all the cost and expenses relating to the Trainees, including but not limited to their salaries, round trip airfare between China and Korea, lodgings and meals of Trainees in Korea, transportation and insurance;

      (iii) Licensor shall provide working lunches for the trainees during working days and transportation for the trainees between dormitory and training site.

      (iv) Licensee shall pay to Licensor as training fee, payable upon demand, US$300 per Trainee per day, as the compensation of training services provided by Licensor;

      (v) Licensee shall instruct the Trainees to observe and abide by all rules and regulations of Licensor and the laws of Korea during their training period;

      (vi) All Trainees shall be insured at the expense of Licensee by an internationally recognized accident compensation insurance during the entire training period between their departure from and return to China;

      (vii) Licensee shall indemnify and hold harmless Licensor against any loss, damage, claim, liabilities, cost or expense arising out of any act of a Trainee or any injury or death of the Trainee or any damage to his/her property.

 

2.5   SUPPORT OF TESTS

Pursuant to the terms of a purchase order, sale agreement or other document to be separately agreed by the Parties or Licensee and Delphi, Licensor will support the necessary manufacturing Part Production Approval Process validation tests for the Licensed Products.

 

2.6   SAMPLE TEST AND VERIFICATION

Before distribution and sale of any of the Licensed Product manufactured or assembled hereunder, Licensee shall submit, at its expense, samples of the Licensed Product for approval by Licensor. Licensor shall promptly conduct appropriate tests on such samples and advise Licensee of the results thereof. The costs of any tests on the samples shall be responsibility of Licensee, and Licensor shall advise Licensee of the test fees in advance.

 

KASAN_국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 기술지원 TECHNICAL ASS

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.06.04 08:47
Trackback 0 : Comment 0

댓글을 달아 주세요


11. REPRESENTATIONS AND WARRANTIES.

11.1 The Parties ’Representations and Warranties.

Each Party hereby represents, warrants and covenants to the other Party, as of the Effective Date (or as of the Closing Date in the case of Section 11.1(h)), that:

(a) such Party (i) is a corporation duly organized and validly existing under the laws of its jurisdiction of organization, and (ii) has full power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as it is contemplated to be conducted by this Agreement;

 

(b) such Party has sufficient legal and/or beneficial title under its intellectual property rights necessary for the purposes contemplated under this Agreement and to grant the licenses contained in this Agreement;

 

(c) such Party is not aware of any pending or threatened litigation, nor has it received any notice of claim, alleging that it has violated or would violate, through the manufacture, import and/or sale of Licensed Products hereunder, or by conducting its obligations as currently proposed under this Agreement, any intellectual property or other rights of any Third Party;

 

(d) to such Party’s knowledge, all of its employees, officers, independent contractors, consultants and agents have executed agreements requiring assignment to such Party of all inventions made during the course of and as a result of their association with such Party and obligating the individual to maintain as confidential the Confidential Information of such Party;

 

(e) such Party has the power, authority and legal right, and is free to enter into this Agreement and, in so doing, will not violate any other agreement to which such Party is a party as of the Effective Date and such Party has maintained and will maintain and keep in full force and effect all agreements and regulatory filings necessary to perform its obligations under the Agreement and, during the Term, such Party shall not enter into any agreement with a Third Party that will conflict with the rights granted to the other Party under this Agreement;

 

(f) this Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation of such Party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity;

 

(g) such Party has taken all corporate action necessary to authorize the execution, delivery and performance of this Agreement;

 

(h) such Party has obtained all consents, approvals and authorizations of all Regulatory Authorities and other Third Parties reasonably deemed necessary by such Party to be obtained in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder;

 

(i) the execution and delivery of this Agreement and the performance of such Party’s obligations hereunder: (i) do not conflict with or violate any provision of the certificate of incorporation, bylaws, limited partnership agreement or any similar instrument of such Party, as applicable, in any material way; (ii) to such Party’s knowledge, do not conflict with, violate or breach or constitute a default or require any consent under any indenture, mortgage, contract or instrument to which it is party or by which it is bound; and (iii) to such Party’s knowledge, do not conflict with, violate, or breach or constitute a default or require any consent under, any requirement of Applicable Laws or court or administrative order by which such Party is bound;

 

(j) except in connection with or related to the settlement between Licensee A and the United States Department of Justice, announced on September 1, 2010, neither such Party, nor any of such Party’s employees, officers, independent contractors, consultants or agents who will render services relating to Licensed Products: (i) has ever been debarred or is subject to debarment or convicted of a crime for which an entity or person could be debarred under 21 U.S.C. Section 335a; or (ii) has ever been under indictment for a crime for which a person or entity could be debarred under said Section 335a. If during the Term a Party has reason to believe that it or any of its employees, officers, independent contractors, consultants or agents rendering services relating to Licensed Products: (x) is or will be debarred or convicted of a crime under 21 U.S.C. Section 335a; or (y) is or will be under indictment under said Section 335a, then such Party shall immediately notify the other Party of same in writing; and

 

(k) such Party currently has no research or development project, or agreement with any Third Party, that, in such Party’s reasonable scientific or business judgement, (i) requires or is likely to require changes to the Development Plan attached hereto as Exhibit 4.1, or (ii) is likely to interfere with such Party’s ability to enter into and perform its obligations under this Agreement.

 

11.2 Representations and Warranties of Licensor M.

Licensor M hereby represents, and warrants and covenants to Licensee A, as of the Effective Date, that:

(a) Licensor M is the sole and exclusive owner of all right, title and interest, in, to and under the Licensed Intellectual Property in the Territory;

 

(b) M is the sole and exclusive owner of all right, title and interest, in, to under the Licensed Intellectual Property necessary or useful in the Manufacture of Licensed Products;

 

(c) M has sufficient rights to grant the rights and licenses granted herein, free and clear of any security interests, claims, encumbrances or charges of any kind that would conflict in any material respect with the rights and licenses granted hereunder;

 

(d) M has not assigned or granted to any Third Party any rights under the Licensed Intellectual Property that cover Licensed Products in the Territory except as granted to independent contractors in the ordinary course of business in connection with M's research, Development and Manufacturing of Licensed Products, and consistent with the terms and intent of this Agreement;

 

(e) (i) M has not received any written notice from any Third Party asserting or alleging that any Development, Manufacturing, or Commercialization of the Licensed Products has infringed or misappropriated any Patent or intellectual property right of such Third Party, (ii) to the knowledge of M, the manufacture, use, offer for sale, sale or importation of Licensed Products in the Territory has not infringed and, as of the Effective Date, will not infringe, any Patent of any Third Party or misappropriate any technology of any Third Party, and (iii) there are no pending, and, to the knowledge of M, no threatened, adverse actions, suits, arbitrations, litigations, or proceedings of any nature, civil, criminal, regulatory or otherwise, in law or in equity, against M or any of its Affiliates alleging that the Development, Manufacture, Commercialization or other exploitation of Licensed Products has infringed any Patent, or misappropriated any intellectual property right of any Third Party;

 

(f) to Licensor M’s knowledge, the issued Patents within the M Patent Rights in the Territory are valid and enforceable;

 

(g) all applicable maintenance and renewal fees with respect to the M Patent Rights in the Territory have been paid and all documents, and certificates required to be filed for the purpose of maintaining such M Patent Rights have been filed;

 

(h) to Licensor M’s knowledge, no Third Party has asserted that any Licensed Intellectual Property is invalid or not enforceable;

 

(i) (i) other than as disclosed by M in writing to A prior to the Effective Date, none of the M Patent Rights, were developed with federal or state funding from any Governmental Authority, (ii) no Governmental Authority has any march in rights or other rights to use the Licensed Intellectual Property in the Territory, and (iii) neither the execution and delivery of this Agreement nor the performance hereof by M will result in the breach of, or give rise to, any right of termination, rescission, renegotiation or acceleration under, or trigger any other rights under, any agreement or contract to which M is a party, or to which it may be subject, that relates to the Licensed Products;

 

(j) no written communication has been received by M from any Third Party that alleges, and there is no pending litigation that alleges, that (i) any issued M Patent is invalid or unenforceable as of the Effective Date, or (ii) any patent application included in the M Patents, if issued, would be, invalid or unenforceable;

 

(k) to the knowledge of Licensor M, no Third Party (i) is infringing any M Patent Rights or has misappropriated any M Know-How, or (ii) has challenged the ownership, scope, duration, validity, enforceability, priority or right to use any M Patent Rights (including, by way of example, through the institution of or written threat of institution of interference, re-examination, review, supplemental examination, derivation proceeding, protest, opposition, nullity or similar invalidity proceeding before the U.S. Patent and Trademark Office or any analogous foreign entity) or any M Know-How;

 

(l) the Licensed Intellectual Property licensed to Licensee A hereunder constitutes all of the intellectual property rights Controlled by M that are necessary for A to Commercialize Licensed Products in the Territory;

 

(m) to Licensor M’s knowledge, M has complied in all material respects with all Applicable Laws in the prosecution and maintenance of the M Patent Rights in the Territory;

 

(n) all of Licensor M’s and its Affiliates’ employees, officers, and consultants/contractors involved in the research, Manufacture or Development of Licensed Products are and have been obligated to assign to M or such Affiliate, as the case may be, all Inventions claimed in the M Patent Rights and to maintain as confidential the Confidential Information of M or such Affiliate, as applicable; and

 

(o) all inventors of any Inventions included within the M Patent Rights and M Know-How have assigned their entire right, title, and interest in and to such Inventions and the corresponding Patents and Information to M and have been listed in the M Patent Rights as inventors.

 

KASAN_특허기술, 영업비밀 실시허락, 기술이전, 라이선스 영문계약서에서 진술 및 보증조항 REPRESENTATI

 

[질문 또는 상담신청 입력하기]

 

 

 

작성일시 : 2019.05.31 16:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

KASAN_특허실시, 기술이전, 공동연구개발, 라이선스 등 국제계약에서 분쟁해결수단 중재조항 관련된 분쟁사례 및 실

 

[질문 또는 상담신청 입력하기]

 

 

 

작성일시 : 2019.05.29 16:01
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

조정 정의

조정(Mediation)은 분쟁 당사자가 조정인의 도움을 받아 당사자 사이의 대화와 상호양해를 통하여 조리(條理)를 바탕으로 분쟁을 실정에 맞게 자율적으로 해결하는 제도입니다. 중립적인 제3자인 조정인이 분쟁 당사자간의 합의를 통해 분쟁을 해결하도록 도와주는 ADR 제도 중의 하나가 조정(調停)입니다.

 

분쟁을 조정에 의하여 해결하기로 하는 합의를 조정합의(調停合意)라고 합니다. 대한상사중재원의 조정을 이용하기 위해서는 분쟁 당사자간에 체결한 계약서나 합의서 등에 '대한상사중재원의 조정규칙에 의한 조정 또는 대한상사중재원의 조정에 따라 해결하기로 합의한 경우' 즉 조정합의가 있는 경우에 해당하여야 합니다.

 

조정합의는 사전 합의(조정 조항)사후 조정합의 형식으로 할 수 있습니다.

 

당사자간에 조정합의가 없는 경우나 사후 조정합의가 곤란한 경우 일방 당사자(신청인)는 중재원에 조정참여 권유요청을 할 수 있습니다. 이 경우 중재원은 타방 당사자(피신청인)에게 조정참여 권유요청을 하고, 피신청인이 동의하면 조정절차를 진행하게 됩니다.

 

조정인의 역할

조정인은 당사자들이 분쟁을 우호적으로 해결하도록 협조하여야 합니다. 조정인은 당사자간의 거래관행 및 분쟁과 관련된 제반 상황 등을 고려하여 공정하고 객관적이며, 형평과 선의 원칙에 따라 분쟁을 조정하여야 합니다. 조정인은 언제든지 구두 또는 서면으로 당사자들에게 조정안을 제시할 수 있습니다.

 

조정인의 의무

조정인은 조정에 관하여 공정성과 독립성을 유지하여야 합니다. 조정인은 그 자신의 공정성 또는 독립성에 관하여 정당한 의문을 야기시킬 수 있는 사유가 있을 때에는 지체없이 이를 사무국에 고지하여야 합니다. 사무국은 조정인으로부터 그러한 고지를 받으면 즉시 당사자들에게 통지합니다.

 

조정절차 개요

 

KASAN_대한상사중재원의 조정 (Mediation) 개요 설명 – 중재(Arbitration)와 엄격하게 구별.p

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.29 09:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

3(정의) 이 법에서 사용하는 용어의 뜻은 다음과 같다.

1. "중재"란 당사자 간의 합의로 재산권상의 분쟁 및 당사자가 화해에 의하여 해결할 수 있는 비재산권상의 분쟁을 법원의 재판에 의하지 아니하고 중재인의 판정에 의하여 해결하는 절차를 말한다.

2. "중재합의"란 계약상의 분쟁인지 여부에 관계없이 일정한 법률관계에 관하여 당사자 간에 이미 발생하였거나 앞으로 발생할 수 있는 분쟁의 전부 또는 일부를 중재에 의하여 해결하도록 하는 당사자 간의 합의를 말한다.

 

8(중재합의의 방식) ① 중재합의는 독립된 합의 또는 계약에 중재조항을 포함하는 형식으로 할 수 있다. ② 중재합의는 서면으로 하여야 한다.

 

③ 다음 각 호의 어느 하나에 해당하는 경우는 서면에 의한 중재합의로 본다.

1. 구두나 행위, 그 밖의 어떠한 수단에 의하여 이루어진 것인지 여부와 관계없이 중재합의의 내용이 기록된 경우

2. 전보, 전신, 팩스, 전자우편 또는 그 밖의 통신수단에 의하여 교환된 전자적 의사표시에 중재합의가 포함된 경우. 다만, 그 중재합의의 내용을 확인할 수 없는 경우는 제외한다.

3. 어느 한쪽 당사자가 당사자 간에 교환된 신청서 또는 답변서의 내용에 중재합의가 있는 것을 주장하고 상대방 당사자가 이에 대하여 다투지 아니하는 경우

 

④ 계약이 중재조항을 포함한 문서를 인용하고 있는 경우에는 중재합의가 있는 것으로 본다. 다만, 중재조항을 그 계약의 일부로 하고 있는 경우로 한정한다.

 

9(중재합의와 법원에의 제소) ① 중재합의의 대상인 분쟁에 관하여 소가 제기된 경우에 피고가 중재합의가 있다는 항변을 하였을 때에는 법원은 그 소를 각하하여야 한다. 다만, 중재합의가 없거나 무효이거나 효력을 상실하였거나 그 이행이 불가능한 경우에는 그러하지 아니하다. ② 피고는 제1항의 항변을 본안에 관한 최초의 변론을 할 때까지 하여야 한다. ③ 제1항의 소가 법원에 계속 중인 경우에도 중재판정부는 중재절차를 개시 또는 진행하거나 중재판정을 내릴 수 있다.

 

35(중재판정의 효력) 중재판정은 양쪽 당사자 간에 법원의 확정판결과 동일한 효력을 가진다. 다만, 38조에 따라 승인 또는 집행이 거절되는 경우에는 그러하지 아니하다.

 

36(중재판정 취소의 소) ① 중재판정에 대한 불복은 법원에 중재판정 취소의 소를 제기하는 방법으로만 할 수 있다.

 

② 법원은 다음 각 호의 어느 하나에 해당하는 경우에만 중재판정을 취소할 수 있다.

1. 중재판정의 취소를 구하는 당사자가 다음 각 목의 어느 하나에 해당하는 사실을 증명하는 경우

. 중재합의의 당사자가 해당 준거법에 따라 중재합의 당시 무능력자였던 사실 또는 중재합의가 당사자들이 지정한 법에 따라 무효이거나 그러한 지정이 없는 경우에는 대한민국의 법에 따라 무효인 사실

. 중재판정의 취소를 구하는 당사자가 중재인의 선정 또는 중재절차에 관하여 적절한 통지를 받지 못하였거나 그 밖의 사유로 변론을 할 수 없었던 사실

. 중재판정이 중재합의의 대상이 아닌 분쟁을 다룬 사실 또는 중재판정이 중재합의의 범위를 벗어난 사항을 다룬 사실. 다만, 중재판정이 중재합의의 대상에 관한 부분과 대상이 아닌 부분으로 분리될 수 있는 경우에는 대상이 아닌 중재판정 부분만을 취소할 수 있다.

. 중재판정부의 구성 또는 중재절차가 이 법의 강행규정에 반하지 아니하는 당사자 간의 합의에 따르지 아니하였거나 그러한 합의가 없는 경우에는 이 법에 따르지 아니하였다는 사실

 

2. 법원이 직권으로 다음 각 목의 어느 하나에 해당하는 사유가 있다고 인정하는 경우

. 중재판정의 대상이 된 분쟁이 대한민국의 법에 따라 중재로 해결될 수 없는 경우

. 중재판정의 승인 또는 집행이 대한민국의 선량한 풍속이나 그 밖의 사회질서에 위배되는 경우

 

③ 중재판정 취소의 소는 중재판정의 취소를 구하는 당사자가 중재판정의 정본을 받은 날부터 또는 제34조에 따른 정정ㆍ해석 또는 추가 판정의 정본을 받은 날부터 3개월 이내에 제기하여야 한다. ④ 해당 중재판정에 관하여 대한민국의 법원에서 내려진 승인 또는 집행 결정이 확정된 후에는 중재판정 취소의 소를 제기할 수 없다.

 

37(중재판정의 승인과 집행) ① 중재판정은 제38조 또는 제39조에 따른 승인 거부사유가 없으면 승인된다. 다만, 당사자의 신청이 있는 경우에는 법원은 중재판정을 승인하는 결정을 할 수 있다. ② 중재판정에 기초한 집행은 당사자의 신청에 따라 법원에서 집행결정으로 이를 허가하여야 할 수 있다. ③ 중재판정의 승인 또는 집행을 신청하는 당사자는 중재판정의 정본이나 사본을 제출하여야 한다. 다만, 중재판정이 외국어로 작성되어 있는 경우에는 한국어 번역문을 첨부하여야 한다. ④ 제1항 단서 또는 제2항의 신청이 있는 때에는 법원은 변론기일 또는 당사자 쌍방이 참여할 수 있는 심문기일을 정하고 당사자에게 이를 통지하여야 한다. ⑤ 제1항 단서 또는 제2항에 따른 결정은 이유를 적어야 한다. 다만, 변론을 거치지 아니한 경우에는 이유의 요지만을 적을 수 있다. ⑥ 제1항 단서 또는 제2항에 따른 결정에 대해서는 즉시항고를 할 수 있다. ⑦ 제6항의 즉시항고는 집행정지의 효력을 가지지 아니한다. 다만, 항고법원(재판기록이 원심법원에 남아 있을 때에는 원심법원을 말한다)은 즉시항고에 대한 결정이 있을 때까지 담보를 제공하게 하거나 담보를 제공하게 하지 아니하고 원심재판의 집행을 정지하거나 집행절차의 전부 또는 일부를 정지하도록 명할 수 있으며, 담보를 제공하게 하고 그 집행을 계속하도록 명할 수 있다. ⑧ 제7항 단서에 따른 결정에 대해서는 불복할 수 없다.

 

KASAN_중재법 주요조항 정리.pdf

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.29 08:21
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

2. LICENSE GRANT. 

2.1 License Grant to A. 

Subject to the terms and conditions of this Agreement, Licensor M hereby grants to Licensee A an exclusive (even as to M and its Affiliates), royalty-bearing license, with the right to grant sublicenses through multiple tiers (subject to Section 2.2), under the M Know-How and M Patent Rights, to Develop, manufacture, use, sell, offer for sale, import, export and otherwise Commercialize Licensed Products in the Territory subject to and in accordance with the terms and conditions of this Agreement.  The foregoing license includes the right to have any of the foregoing performed pursuant to Section 2.2.

 

2.2 Sublicense and Subcontracting Rights. 

Licensee A shall require A’s Sublicensees to agree in writing to be bound by all of the applicable terms and conditions of this Agreement. A’s grant of any sublicense shall not relieve A from any of A’s obligations under this Agreement, and A shall remain jointly and severally liable for any uncured breach of a sublicense by a Sublicensee of A to the extent that such uncured breach would constitute a breach of this Agreement. A shall have the right to retain a Third Party contractor to perform any activity in connection with A’s exercise of any of its rights granted under Section 2.1, where such activity is to be performed at the direction and control and for the sole benefit of A or its Affiliates. A shall ensure that any and all activities performed by the Third Party contractor comply in all respects with the terms and conditions of this Agreement, and shall remain primarily liable for all such activities of the Third Party contractor. Such retention of the Third Party contractor is not a sublicense within the meaning of this Section 2.2 but is considered an activity of A under the license granted in Section 2.1. 

 

2.3 Certain Restrictions.  

(a) Except as otherwise expressly provided in Section 2.4, Licensor M agrees that it shall not, and will cause its Affiliates to not, offer to sell, license or otherwise provide any rights, including for example distribution rights, to Licensed Products, or under M Patent Rights or M Know How, to any Third Party if M or its relevant Affiliates, knows, or has a reason to believe (i) that such Licensed Product would be sold or transferred into the Territory; or (ii) that M Patent Rights or M Know How would be used, directly or indirectly, to manufacture, develop or commercialize a Licensed Product, or any product that would be reasonably expected to compete with a Licensed Product, or any product that would infringe at least one Valid Claim of a M Patent Right, which product, in each case, would be sold or transferred into the Territory. M agrees that it will include a provision in any contracts with its Sublicensees obligating such party to refrain from actions described in this Section 2.3(a). 

 

(b) Licensee A agrees that it shall not, and will cause its Affiliates to not, (i) offer to sell or otherwise provide Licensed Products to any Third Party if A or its relevant Affiliates, knows, or has reason to believe that the Licensed Product offered for sale, sold or provided to such Third Party would be, directly or indirectly, sold or transferred into North Korea or into South Korea; and (ii) use or practice under any intellectual property right licensed to it under this Agreement except as expressly permitted by this Agreement.  A agrees that it will include a provision in any contracts with its Sublicensees obligating such party to refrain from such actions described in Section 2.3(b)(i) and (ii).  

 

2.4 Reservation of Rights.  

(a) Notwithstanding Section 2.1 and Section 2.3, Licensor M shall retain the right to (i) Manufacture Licensed Products and supply such Licensed Products to A pursuant to the terms of the Supply Agreement, (ii) develop, manufacture, use, sell, offer for sale, import, export and otherwise commercialize the M Products anywhere in the world, (iii) subject to Section 2.5, develop, manufacture, use, sell, offer for sale, import, export and otherwise commercialize MT10 (but not any formulation thereof other than the lyophilized formulation of M’s proprietary 150kDa botulinum toxin type A product without human serum albumin) anywhere in the world either itself or through a Third Party, and (iv) develop, manufacture and use, sell, offer for sale, import, export and otherwise commercialize, under the M Know-How and M Patent Rights, any M Product that complies with cGMP (a “cGMP M Product”) anywhere in the world either by itself or through a Third Party; provided that, notwithstanding anything to the contrary, if M develops any cGMP M Product, M shall not, and shall not license, authorize or otherwise permit any Third Party to, at any time during the Term, (A) file for Regulatory Approval of a cGMP M Product in any country in the Territory as a “biosimilar” or a “follow-on biologic” or a “subsequent entry biologic” or other comparable term under applicable regulatory regimes in such country, or (B) market, promote, sell, offer for sale, import, export or otherwise commercialize a cGMP M Product anywhere in the United States or anywhere in Canada or in any Member country of the European Union.

 

(b) Notwithstanding Section 2.1 and Section 2.3, Licensor M shall retain the right to use, sell, offer for sale, import, export and otherwise Commercialize MT10 in Japan, but only in Japan and in no other country in the Territory; provided that (i) M and A shall be co-exclusive with respect to such activities with respect to MT10 in Japan, (ii) M may not sell, offer for sale or otherwise Commercialize either MT10 in Japan through any importer or distributor on a “named patient basis” or otherwise, and (iii) M shall have no right to grant sublicense rights to any Third Party with respect to MT10 in Japan but shall have the right to grant sublicense rights to an Affiliate of M in Japan; provided that, with respect to any such Affiliate, (A) M has a one hundred percent (100%) controlling interest over any decision regarding the sale or other distribution of products by such Affiliate and (B) no competitor of A has any control or equity interest in such Affiliate, in both (A) and (B), as of the effective date of such sublicense and remains so throughout the term of the sublicense. For purposes of clarification, in the event that M grants a sublicense to an Affiliate of M pursuant to (iii) above and, at any time after the effective date of the sublicense, either (1) M does not have a one hundred percent (100%) controlling interest over any decision regarding the sale or other distribution of products by such Affiliate or (2) a competitor of A acquires any control or equity interest in such Affiliate whether by, for example, investment, acquisition or merger, M agrees that such sublicense shall terminate. In connection with such M retained right, A agrees that it shall not sell, offer for sale or otherwise Commercialize either MT10 in Japan through any importer or distributor on a “named patient basis” or otherwise.   

 

2.5 Right of First Refusal. 

If Licensor M wishes to seek Regulatory Approval for and Commercialize MT10 with any Third Party, including without limitation by way of license, partnership, joint venture, collaboration, distribution or other similar relationship, Licensee A shall have a right of first refusal to obtain an exclusive (even as to M and its Affiliates) right and license to MT10 in the Territory.  M shall present to A, prior to any discussion with any Third Party, a complete data package summarizing all available data with respect to the MT10 program and a good faith proposal of terms and conditions for A to obtain an exclusive right and license to MT10, and the Parties shall comply with the procedure set forth in this Section 2.5. The Parties shall proceed promptly to negotiate the terms of a definitive agreement, and shall use commercially reasonable efforts to do so within one hundred and twenty (120) days after initiating such negotiations. In the event that A and M have not agreed upon the material terms and conditions pursuant to which A would receive such a right and license to MT10 within such one hundred and twenty (120) day period after the initiation of discussions (the “ROFR Period”), M shall be free to discuss terms and conditions for the grant of rights and license with respect to MT10 with any Third Party; provided that the terms and conditions offered to the Third Party are not more favourable to such Third Party than those that have been offered to A.  If M has not entered into a definitive written agreement with a Third Party with respect to MT10 within nine (9) months after the later of (i) the date of the expiration of the ROFR Period and (ii) the date of the termination of the negotiations between M and A regarding the terms and conditions of a license to MT10, then M shall not offer to any Third Party any rights to MT10 unless and until M has first offered A a further right of first refusal to obtain such a license, which further right of first refusal shall operate in accordance with the terms of this Section 2.5. 

 

2.6 No Implied Rights or Licenses. 

Licensor M grants no additional rights or licenses in or to any Patent or other intellectual property right, whether by implication, estoppel or otherwise, except to the extent expressly provided for under this Agreement.

 

KASAN_특허실시, 영업비밀, 기술이전 라이선스 및 생산공급 계약서에서 LICENSE GRANT 계약조항 샘플.p

 

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.28 13:04
Trackback 0 : Comment 0

댓글을 달아 주세요


 

실무적 포인트

·         진술 및 보증 조항 Rep. & Warranty

Ø  소유권/license허여권 보증 ()

Ø  계약대상 IP의 권리 유효성 보증 (적법 등록유지 , 절대적 유효성 ×)

Ø  3자의 지재권 비침해 보증 (고의침해 ○, 기타 )

 

·         면책 Indemnification

Ø  지재권 침해 claim시 면책규정은 license, 공동연구발 계약협상에서 쟁점이 많은 규정

Ø  특허를 제외한 copyright등 기타 권리에 대해서는 indemnification을 대부분 수용하는 편이나, 특허에 대해서는 면책보장의 수용이 어려운 경우가 많음. 

Ø  전세계 특허의 사전조사는 현실적으로 불가능하고, 고의적으로 copy한 경우가 아니더라도 유사성이 존재하는 한 침해를 구성  

Ø  반면, 저작권 등의 경우는 제3자의 저작물을 copy한 경우가 아니라면, 독자개발에 의해 발명/발견된 경우는 유사성이 존재하더라도 침해를 구성치 않음 

Ø  고의침해 경우(punitive damage대상이 됨) - 무제한 배상 보장 가능

Ø  기타 지재권 침해 claim경우 - 지불금액 총액 한도내에서 합의가 합리적  

Ø  제외: - 허여 용도 외 사용, 제공기술/제품의 임의 수정, 제공 외 기술/제품과 결합, 합성 등으로 인해 침해가 발생한 경우         

 

계약조항 영문 샘플

23. INDEMNIFICATION; INSURANCE; LIMITATION OF LIABILITY. 

23.1 General Indemnification by Licensor. Licensor CyDex shall defend, indemnify and hold Licensee Hospira and its Affiliates and Sublicensees, and each of their respective directors, officers, agents and employees, harmless from and against any and all losses, judgments, damages, liabilities, settlements, penalties, fines, costs and expenses (including the reasonable costs and expenses of attorneys and other professionals) (collectively “Losses”) incurred as a result of any claim, demand, action or other proceeding (each, a “Claim”) by a Third Party, to the extent such Losses arise out of: (a) the manufacture, use, handling, promotion, marketing, distribution, importation, sale or offering for sale of Captisol by CyDex, its Affiliates or any of their agents, or (b) CyDex’s breach of this Agreement, including without limitation any of its representations and warranties set forth in Section 8, or (c) any negligent or willful misconduct by CyDex or its Affiliates or any of their respective distributors, officers, directors employees or agents, in each case to the extent that such Losses are not due to Hospira’s or any of its Affiliates’ or Sublicensees’, or any of their respective directors’, officers’, agents’ or employees’ breach of this Agreement or negligence or willful misconduct.

 

23.2 General Indemnification by Licensee. Licensee Hospira shall defend, indemnify and hold Licensor CyDex and its Affiliates, and each of their respective directors, officers, agents and employees, harmless from and against any and all Losses incurred as a result of any Claim by a Third Party, to the extent such Losses arise out of: (a) the manufacture, use, handling, promotion, marketing, distribution, importation, sale or offering for sale of the Finished Product by Hospira, its Affiliates and Sublicensees, or (b) Hospira’s breach of this Agreement, including without limitation any of its representations and warranties set forth in Section 8, or (c) any negligent or willful misconduct by Hospira or its Affiliates or any of their respective distributors, officers, directors employees or agents, in each case to the extent that such Losses are not due to CyDex’s or any of its Affiliates’ or any of their respective directors’, officers’, agents’ or employees’ breach of this Agreement or negligence or willful misconduct.

 

23.4 Procedure.

 

(a) The person intending to claim indemnification under Section 9 (an “Indemnified Party”) shall promptly notify the other party (the “Indemnifying Party”) of any Claim in respect of which the Indemnified Party intends to claim such indemnification, and a reasonable explanation of the basis for the Claim and the amount of alleged Losses to the extent of the facts then known by the Indemnified Party. (Notwithstanding the foregoing, no delay or deficiency on the part of the Indemnified Party in so notifying the Indemnifying Party will relieve the Indemnifying Party of any liability or obligation under this Agreement except to the extent the Indemnifying Party has suffered actual prejudice directly caused by the delay or other deficiency.) The Indemnifying Party shall assume the defense thereof; provided, however, that if the Indemnifying Party assumes the defense, the Indemnified Party shall have the right to employ counsel separate from counsel employed by the Indemnifying Party in any such action and to participate in the defense thereof, but the fees and expenses of such counsel employed by the Indemnified Party shall be at the sole cost and expense of the Indemnified Party unless the Indemnifying Party consents to the retention of such counsel or unless the named parties to any action or proceeding include both the Indemnifying Party and the Indemnified Party and a representation of both the Indemnifying Party and the Indemnified Party by the same counsel would be inappropriate due to the actual or potential differing interests between them. And provided further that, if the Indemnifying Party shall fail to assume the defense of and reasonably defend such Claim, the Indemnified Party shall have the right to retain or assume control of such defense and the Indemnifying Party shall pay (as incurred and on demand) the fees and expenses of counsel retained by the Indemnified Party.

 

(b) The Indemnifying Party shall not be liable for the indemnification of any Claim settled (or resolved by consent to the entry of judgment) without the written consent of the Indemnifying Party (which shall not be unreasonably withheld or delayed). Also, if the Indemnifying Party shall control the defense of any such Claim, the Indemnifying Party shall have the right to settle such Claim; provided, that the Indemnifying Party shall obtain the prior written consent (which shall not be unreasonably withheld or delayed) of the Indemnified Party before entering into any settlement of (or resolving by consent to the entry of judgment upon) such Claim unless (A) there is no finding or admission of any violation of law or any violation of the rights of any Third Party by an Indemnified Party, no requirement that the Indemnified Party admit fault or culpability, and no adverse effect on any other claims that may be made by or against the Indemnified Party and (B) the sole relief provided is monetary damages that are paid in full by the Indemnifying Party and such settlement does not require the Indemnified Party to take (or refrain from taking) any action.

 

(c) Regardless of who controls the defense, the other party hereto shall reasonably cooperate in the defense as may be requested. Without limitation, the Indemnified Party, and its directors, officers, advisers, agents and employees, shall reasonably cooperate with the Indemnifying Party and its legal representatives in the investigations of any Claim.

 

23.5 Insurance. CyDex will procure and maintain, at its own expense, for the duration of the Agreement, and for [*] thereafter if written on a claims made or occurrence reported form, the types of insurance specified below with carriers rated [*]. Best or like rating agencies:

  a. Workers’ Compensation accordance with applicable statutory requirements and shall provide a waiver of subrogation in favor of Hospira; 

  b. Employer’s Liability with a limit of liability in an amount of not less than $[***]; 

  c. Commercial General Liability including premises operations, products & completed operations, blanket contractual liability, personal injury including fire legal liability for bodily injury and property damage in an amount not less than $[***]; 

  d. Commercial Automobile Liability for owned, hired and non-owned motor vehicles with a combined single limit in an amount not less than $[*];  

  e. Excess Liability including product liability with a combined single limit in an amount of not less than $[*]; 

  f. Commercial Crime or Fidelity Bond in an amount of not less than $[*] including an endorsement for Third Party liability without the requirement of a conviction. 

  g. Cargo Legal Liability insurance covering all risks of physical loss or damage to cargo handled by CyDex. The limit of liability shall not be less than $[*]. 

 

23.6 Limitation of Liability. EXCEPT FOR (1) PERSONAL INJURY, INCLUDING DEATH, (2) TANGIBLE PROPERTY DAMAGE, (3) EACH PARTY’S INDEMNIFICATION OBLIGATIONS, (4) DAMAGES ARISING OUT OF AN INTENTIONAL BREACH OF THE CONFIDENTIALITY OBLIGATIONS HEREIN, (5) DAMAGES ARISING OUT OF CYDEX’S BREACH OF SECTION 2.4, AND (6) DAMAGES FOR WHICH CYDEX IS RESPONSIBLE PURSUANT SECTION 3.6, 3.7 OR 6.4.

 

KASAN_특허실시, 기술이전, 라이선스 영문계약서에서 진술보증, 면책조항 관련 실무적 포인트 몇 가지 면책조항

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.23 10:02
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

KASAN_특허실시, 기술이전 라이선스, 공동연구개발계약에서 추가 연구개발 결과물, 개량발명 관련 계약조항 샘플,

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.23 09:43
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

기술사용료 vs 기술지원 용역비 구분

 

구분

사용대가 사용료

개념

특허, 상표, 저작권, 기술 등 무형의 가치

원천지기준

국내세법 : 사용 또는 지급지국 기준

(국내에서 권리의 사용 또는 대가지급 시)

 

조세조약(우선 적용)

대부분의 경우 : 지급지국 기준

미국, 태국 : 사용지국 기준

헝가리 : 거주지국 배타적 과세

소득성격

기존에 창출된 가치에 대한 대가

제공자 책임

결과에 대한 보증의무 없음

기타 기술용역

특허권 등이나 노하우 제공에 필연적으로 부수되는 용역대가

인적용역대가와

사용료가 혼합된 경우

인적용역 부분이 보조적이며 그 금액이 크지 않은 경우 전체를 사용료로 봄

관련 물품 수입 관세 기준

수입물품에 대한 관세의 과세가격은 우리나라로 수출, 판매되는 물품에 대하여 수입자가 실제로 지급하였거나 지급하여야 할 가격에 ‘상표권 및 이와 유사한 권리를 사용하는 대가(상표사용료 + 국제마케팅비용)’ 등을 가산ㆍ조정하여 산정한 거래가격에 의하여 결정

 

구분

기술지원 용역비

개념

신체에 부수되어 제공되는 노무, 기능 및 기술

원천지기준

국내세법 : 수행지국 과세

 

조세조약(국내세법에 우선적용)

원칙: 거주지국 과세

특례: 수행지국 과세 (다음 하나에 해당 시)

       1. 고정시설 유지

       2. 장기체류요건(183일 초과 체재)

       3. 수취금액요건(일정금액 초과지급)  

※ 수행지국 과세요건은 조세조약별로 상이

소득성격

서비스에 대한 대가

제공자 책임

일정기간 동안 용역결과에 대해 보증의무 있음

기타 기술용역

용역제공에 따른 인적물적비용으로 실제 소요된 비용

인적용역대가와

사용료가 혼합된 경우

인적용역 부분이 합리적으로 구분가능하고 그 인적용역 부분이 사용료의 보조적이 아니며 금액이 큼

관련 물품 수입 관세 기준

개발비지급 목적이 시제품을 전달이 아니고 계약제품의 설계 등 양산을 위한 기술정보를 도입하기 위한 경우, 성능시험을 위해 반입되는 시제품의 과세가격은 용역개발비 전액이 아니라, 시제품 제작을 위해 사용된 원자재비용 및 조립 기타 가공에 소요된 비용을 과세가격으로 결정

 

로열티 지급과 세금 원천징수

 

원천소득이란 당해 소득의 원천이 되는 소재지 등이 국내인 소득을 말하며 이를 근거로 각국이 외국법인에 대해서도 과세할 수 있습니다. 우리나라 세법은 국내 원천소득을 열거하고 있고 규정되지 않은 사항은 과세 대상이 아닙니다. 원천징수란 국내사업장이 없는 외국법인에 특허사용료를 지급하는 경우와 같이 외국법인이 국내에서 올린 소득에 대하여 세금을 낼 것을 기대하기 어려운 경우 그 소득을 지급하는 자가 미리 일정액을 떼어 우리 국세청에 납부하도록 하는 제도를 말합니다.  

 

그런데, 같은 기간 동안 동일소득에 대하여 2개국에서 중복 과세한다면 부당하기 때문에, 대부분 이중과세를 방지하기 위한 조약을 체결하고 있습니다. 이중과세 방지는 (1) 특정소득에 대하여 당해 소득의 원천지국에서 세금을 면제하여 주고 거주지국에서만 과세하도록 하는 방법, (2) 원천지 국가에서 과세하고 그 소득에 대해 거주지 국가에서 공제해주는 방법을 활용합니다. 그 중 원천징수를 하지 않는 경우 원천지국가의 조세수입을 감소시키는 측면이 있어서 통상 두 번째 내용의 조세조약으로 해결합니다. 따라서, 특별한 경우가 아닌 한 지급하는 기술료에 대해 원천징수하는 것이 원칙입니다

 

그러나, 당사국 사이 조세조약에 따라 우리나라에 과세권이 없는 경우라면 국내기업이 원천징수를 할 수 없습니다. 예를 들어 특허권자 법인이 아일랜드 소재 기업인 경우 한국 아일랜드 조세협약에 따라 우리나라에서 원천징수를 할 수 없습니다. 이와 같은 이유로 애플, 화이자 등 많은 다국적 거대기업들이 아일랜드에 설립한 법인에 다수의 특허권을 양도하고, 기술 로열티를 아일랜드 법인 귀속으로 하는 경우가 많습니다

 

만약, 국내기업이 외국법인에게 특허 사용료를 지급하면서 세금을 원천 징수하여야 함에도 잘못하여 이를 하지 않는 경우에는 국내기업이 그 해당부분에 대한 원천세를 부과받을 위험이 있습니다. 따라서, 원천징수 여부를 정확하게 확인해야만 이와 같은 부담을 피할 수 있습니다

 

예를 들어, 아일랜드 법인이 세금 회피 목적으로 설립된 실체가 없는 Paper Company인 경우 국세청은 그 아일랜드 법인의 실체를 부인하고 그 소득의 실질 귀속자(그 법인의 투자자 등)를 찾아 한국과 그 실질 귀속자들의 거주국간의 조세조약에 따라 과세할 수 있습니다. , 소득의 실질 귀속자의 국가 세율에 따라 원천징수한 것으로 보고 그 소득에 대한 법인세를 부과할 수 있습니다. 따라서, 국내기업 입장에서는 기술거래 또는 라이선스의 실질적 당사자와 다른 형식적으로 조세회피 목적으로 설립된 paper company에 불과하다는 의문이 든다면 이를 반드시 확인해야 합니다. 상대방이 조세조약을 이유로 기술 로열티에 대한 원천징수를 거부하는 경우라면 그 단계에서 반드시 조세 전문가의 검토 및 확인을 거쳐 적절한 내용으로 계약을 체결하는 것이 바람직합니다. 일단 기술로열티를 모두 지급한 후 상당 기간이 경과하였다면 추후 부과된 세금부담을 해결하기 쉽지 않을 수 있습니다

 

KASAN_기술이전, 라이선스 계약에서 특허기술 사용대가 로열티 vs 기술지원 비용 로열티 구분 로열티 지급과

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.22 15:23
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

미국연방대법원 판결

-      Licensor 상표등록권자 Tempnology vs Licensee 상표사용권자 Mission Product

-      의류 분야 등록상표의 사용허락 라이선스 계약 기간 중 Licensor 상표등록권자 Tempnology 도산 상황 발생 미국법원에 소위 Chapter 11 파산신청 접수

-      미국 파산법에 따라 채무자(debtor)는 이행해야 할 계약상 채무의 이행을 거절하는 부인권(rejection) 행사할 수 있음

-      본 상표사용하락 라이선스 계약에서는 Licensor 상표권자가 채무자로 상대방 채권자, licensee에 대해 라이선스 계약상 채무이행을 거절하는 부인권 행사함.

-      라이센서의 채무는 대상 상표사용을 허여하는 내용이므로 위 부인권 행사로 licensee의 상표사용권한이 소멸되는지 쟁점

-      라이센서의 부인권 행사 후 라이센시가 상표사용을 계속하는 경우 상표권침해에 해당하는지 여부가 쟁점

-      미국연방대법원 라이센시 계속 상표사용권한 인정함

 

미국판결 요지 부정, 라이센시는 대상 상표를 계속 사용할 수 있음

 

 

KASAN_미국연방대법원 2019. 5. 20. 선고 Mission Product vs Tempnology 판결 -

 

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.22 08:39
Trackback 0 : Comment 0

댓글을 달아 주세요


 

 

10. TERMINATION 

10.1 Expiration. Subject to this Section 10 below, this Agreement shall expire, on a Licensed Product-by-Licensed Product and country-by-country basis, on the date on which Kite, its Affiliates and sublicensees permanently cease to research, develop, sell and commercialize the Licensed Product in such country (the “Term”).

 

10.2 Termination for Convenience. The Licensee Kite may terminate this Agreement, in its sole discretion, upon thirty (30) days prior written notice to the Licensor Cabaret and Dr. Eshhar.

 

10.3 Termination for Cause. Except as otherwise provided in Section 12, each party may terminate this Agreement upon or after the breach of any material provision of this Agreement by the other party if the other party has not cured such breach within sixty (60) days (or such longer period as such party may reasonably agree if said breach is incapable of cure within such sixty (60) days) after receipt of express written notice thereof by such party.

 

10.4 Insolvency. This Agreement may be terminated by the Licensor Cabaret in the event of an Insolvency Event occurring in relation to the Licensee Kite, by giving a notice of termination to Kite. The termination shall take effect upon delivery of the notice of termination by Cabaret. “Insolvency Event” shall mean that, with respect to Kite, any of the following occurs: (i) Kite makes any arrangement or composition with or any assignment for the benefit of its creditors generally; (ii) a petition is presented that is not dismissed within 120 days or a court order is made or a resolution is passed for the winding up of Kite or for the making of an administration order or for the appointment of a provisional liquidator or a judicial factor or similar officer in relation to Kite; (iii) an encumbrancer takes possession of or a trustee, receiver, liquidator, provisional liquidator, administrator, manager ad interim, administrative receiver, judicial factor or similar officer is appointed, in each case for all or substantially all of Kite’s intellectual property rights and such appointment materially prejudices Cabaret’s rights under this Agreement; or (iv) Kite does, or suffers to be done in relation to it, any analogous action or proceeding in any jurisdiction anywhere in the world (including without limitation any actions or proceedings relating to bankruptcy law of any nature in the United States of America).

 

10.5 Effect of Expiration or Termination. Expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such expiration or termination, and the provisions of Sections 5.2, 8, 10.5, 10.6, 11 and 13 shall survive the expiration or termination of this Agreement. Upon any termination of this Agreement, all licenses granted herein shall terminate, nevertheless, Cabaret shall grant a direct license to any Sublicensee of Kite hereunder having the same scope as such sublicense and on terms and conditions no less favorable to such Sublicensee than the terms and conditions of this Agreement, provided that such Sublicensee is not in default of any applicable obligations under this Agreement and agrees in writing to be bound by the terms and conditions of such direct license.

 

10.6 Termination Fee. In the event that Kite terminates this Agreement termination for convenience under Section 10.2 prior to the third (3rd) anniversary of the Effective Date, Kite shall pay to Cabaret a termination fee in an amount equal to US$500,000 within thirty (30) days of such termination.

 

KASAN_특허실시, 기술이전, 라이선스 계약서에서 TERMINATION 조항 – 라이센시 파산 등 일반사유 및 양

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.21 14:48
Trackback 0 : Comment 0

댓글을 달아 주세요


계약실무 관행 및 실무적 쟁점

- 실무상 통상적으로 계약해지 Termination 사유로 당사자 부도, 압류, 파산 등을 규정함

- 그러나 국가마다 차이가 있지만 실제 파산 발생 시 termination 조항의 상대방의 계약 해제권 조항은 무효가 되어 아무런 의미가 없는 경우가 많다는 점을 유의해야 함

- 강행법규인 파산법에 따른 파산재산관리/분배규정에 따라, 계약이행상 상당한 변경이 발생할 수 있음

- 미국연방파산법에서는 원칙적으로 미이행계약에 대해서는 파산신청 즉시 automatic stay (자동정지) 발효

- 채무자의 계약상대방은 계약상 허여된 모든 권리 행사는 물론, (금전적 손해배상 청구 외에는) 채무자를 상대로 한 어떤 claim이나 소송도 금지

- 파산관재인은 스스로의 business judgment에 따라, 해당 계약을 거부할 수 있음은 물론(채무자는 계약이행의무가 면제됨), ‘Ipso facto’ 규정 [bankruptcy 발생 시 상대방의 계약 해제권 또는 특정 option 행사권(escrow상 금액/자료 등 인출권한) 발동조항 등]은 무효가 됨

- Licensorbankruptcy 경우에는 해당 license계약상 명시적인 non- assignment 규정이 있는 경우에도, 관재인은 해당 license 계약을 제3자에게 양도할 수 있는 반면,

- (특허 및 저작권법상 IP owner의 동의 없이는 licensee가 해당 license의 양도를 제3자에게 양도하는 것을 금하고 있는 것으로 해석되는 바) licenseebankruptcy에 처한 경우에는 licensor의 동의 없이는 해당 license를 제3자에게 양도, 승계할 수 없다.

- 프랑스, 독일에서는 파산관재인은 라이센스 계약을 미이행 계약으로서 해제할 수 있고, 이것에 대해서 특별한 Licensee 보호 제도는 마련되어 있지 않다.

- , 미국에서는 파산관재인은 미이행 계약인 특허, 저작권, 영업비밀 라이선스 계약(상표/서비스/상호는 제외)의 이행 또는 거절을 선택할 수 있지만,

- 파산관재인이 라이선스 계약의 거절을 선택했을 경우에는 licensee는 라이선스의 유지를 선택할 수 있고, 이 경우 기존 라이센스의 범위 내(, licensor의 특정이행 의무 등의 부수적인 의무는 제외)에서 보호된다.

 

계약실무상 대응방안

- 파산신청 전에 예견될 수 있는 일정 기준 이하의 재정부실, 이행 지연 등을 계약 해지사유로 규정

- 파산신청 전에 발생할 수 있는 Change of control 관련 사안을 해지사유로 규정 라이선스 계약을 미이행계약으로 해석되지 않는 구조로 설정

- : 로열티 지불의무 외에는 실질적인 미이행 의무가 존재치 않도록 규정하고, 다른 의무 (특허 유지/관리의무 등) 는 별도의 미이행계약으로 구성

- Source Code를 제3자 보관 또는 Escrow 위탁 의무가 발생하는 경우를 설정하고, 그 경우 보관/위탁된 source code가 관재인의 control 또는 파산재산 범위에 속하지 않도록 규정 해당 특허권에 대한 담보권 설정

 

미국판결 사안의 쟁점 및 판단 요지

- The question is whether the debtor-licensor’s rejection of that contract deprives the licensee of its rights to use the trademark. We hold it does not.

- 쟁점: 라이센서, 등록권자가 계약서 termination 조항의 사유 파산을 이유로 라이선스 계약을 종료하고 라이센시의 상표사용을 금지할 수 있는지 여부

- 미국대법원 판단요지 부정, 라이센시는 대상 상표를 계속 사용할 수 있음 \

- A rejection breaches a contract but does not rescind it. And that means all the rights that would ordinarily survive a contract breach, including those conveyed here, remain in place.

- 상표사용 허락 라이선스 거절은 계약위반에 해당함

 

첨부: 미국연방대법원 판결

 

KASAN_라이선스 계약서에서 계약해지 (termination) 사유 - 부도, 압류 등 파산, bankruptcy

미국연방대법원 2019. 5. 20. 선고_Mission Product _vs_Tempnology_17-1657_판

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.21 11:40
Trackback 0 : Comment 0

댓글을 달아 주세요


 

10. REPRESENTATIONS, WARRANTIES, AND COVENANTS. 

 

10.1 Mutual Representations and Warranties. Licensor and Licensee (each, a “Representing Party”) each hereby represents and warrants to each other, as of the Effective Date and except as otherwise set forth in Schedule 10.2 (in the case of Licensor) and Schedule 10.3 (the case of Licensee), that:  

 

(a) such Representing Party is a corporation or limited liability company, as applicable, duly organized and subsisting under the laws of its jurisdiction of organization; 

 

(b) such Representing Party has the power, authority, and legal right, and is free, to enter into this Agreement on behalf of itself and its Affiliates and to perform its respective obligations hereunder and to cause its Affiliates to perform their respective obligations hereunder; 

 

(c) such Representing Party has the power, authority, and legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as it is contemplated to be conducted by this Agreement; 

 

(d) this Agreement constitutes a legal, valid, and binding obligation of such Representing Party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered a proceeding at law or equity; 

 

(e) the execution and delivery of this Agreement and the performance of such Representing Party’s and its Affiliates’ obligations hereunder (i) have been duly authorized and approved by all necessary action by such Representing Party, and all necessary consents, approvals, and authorizations of all Regulatory Authorities and other Third Parties required to be obtained by such Representing Party in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained; (ii) do not conflict with or violate any requirement of Applicable Laws or any provision of the articles of incorporation, bylaws, limited partnership agreement, or any similar instrument of such Representing Party, as applicable, in any material way; and (iii) do not, and will not, conflict with or otherwise interfere with in such a manner as to result in a violation, breach, or default under or require any consent that has not been obtained under any contract between such Representing Party and any Third Party; 

 

(f) there are no, and shall be no, liens, conveyances, mortgages, assignments, encumbrances, or other agreements that would prevent or impair such Representing Party’s or any of its Affiliates’ full and complete exercise of the terms and conditions of the Agreement; 

 

(g) such Representing Party and its Affiliates shall at all times comply with all Applicable Laws relating or pertaining to their obligations under the Agreement; 

 

(h) with respect to the services provided hereunder to the other Party, its Affiliates, and their respective employees, officers, contractors and agents who perform such services have the experience, capability, and resources to efficiently and skillfully perform the services, and shall perform, where applicable, all such services in a professional and workmanlike manner and in accordance with the generally accepted then-current standards, forms, procedures, and techniques established from time to time by the industry; 

 

(i) all of such Representing Party’s employees, officers, contractors, and consultants have executed agreements requiring assignment to such Representing Party of all inventions created by such persons in the course of their employment by such Representing Party and obligating each such employee, officer, contractor, and consultant to maintain and safeguard the confidentiality of (i) any information that is confidential to such Representing Party or (ii) any information that is confidential to any other Person and that such Representing Party is obligated to maintain and safeguard as confidential; and

 

(j) neither such Representing Party, nor any of its employees, officers, subcontractors, or consultants who have rendered or will render services relating to the Product: (i) has ever been debarred or is subject or debarment or convicted of a crime for which an entity or person could be debarred under 21 U.S.C. Section 335a or (ii) has ever been under indictment for a crime for which a person or entity could be debarred under said Section 335a. 

 

10.2 Additional Representations, Warranties, and Covenants of Licensor. Licensor hereby represents, warrants, and covenants to Licensee, as of the Effective Date and except as otherwise set forth in Schedule 10.2, that: 

 

(a) Licensor is entitled to grant the rights and licenses purported to be granted to Licensee under this Agreement, and to assign the rights purported to be assigned to Licensee under this Agreement, and is not currently bound by any agreement with any Third Party, or by any outstanding order, judgment, or decree of any court or administrative agency, that restricts it from granting to Licensee the rights, licenses and sublicenses purported to be so granted in this Agreement; 

 

(b) Licensor is the sole and exclusive owner of all right, title, and interest, in, to, and under the Licensed Rights and has the right under the Licensed CPEX Patent Rights and the Licensed Reprise Patent Rights to grant the sublicenses thereunder in accordance with Section 2.2; 

 

(c) the Licensed Rights are free and clear of any liens, charges, encumbrances, or judgments, and Licensor has sufficient rights to grant the licenses and rights purported to be granted herein, free and clear of any security interests, claims, encumbrances, or charges of any kind; 

 

(d) Licensor has not granted, and will not grant during the term of this Agreement, any right, option, license, or interest in or to any of the Licensed Rights that is in conflict with the rights assigned or granted to Licensee under this Agreement; 

 

(e) there is no legal, administrative, arbitration, or other proceeding, suit, claim, or action of any nature, judgment, decree, decision, injunction, writ, or order pending, or to Licensor’s knowledge threatened by, against or involving Licensor, regarding the Licensed Rights, whether at law or in equity, before or by any Third Party, and Licensor has not received any written communications alleging that it has violated, through the manufacture, Development, import, or other exploitation of the Product, any intellectual property rights of any Third Party; 

 

(f) to Licensor’s knowledge: 

(i) the patents in the issued Licensed Serenity Patent Rights, the Licensed CPEX Patent Rights, and the Licensed Reprise Patent Rights are valid and enforceable; and

(ii) no Third Party has asserted that any of the Licensed Rights or the Sublicensed Rights is invalid or unenforceable; 

 

(g) all applications, registrations, maintenance and renewal fees due in respect of any of the Licensed Serenity Patent Rights and, to Licensor’s knowledge, the Licensed Reprise Patent Rights and the Licensed CPEX Patent Rights, have been paid and all documents and certificates required to be filed with the relevant agencies for the purpose of maintaining such Licensed Serenity Patent Rights, and to Licensor’s knowledge, the Licensed Reprise Patent Rights and Licensed CPEX Patent Rights have been filed; 

 

(h) none of the Licensed Serenity Patent Rights, the Licensed Serenity Know-How and, to Licensor’s knowledge, none of the Licensed CPEX Patent Rights and the Licensed Reprise Patent Rights were developed with funding from any Governmental Authority such that any Governmental Authority has any march in rights or other rights to use the Licensed Serenity Patent Rights, the License Serenity Know-How, the Licensed Reprise Patent Rights, or the Licensed CPEX Patent Rights; 

 

(i) to Licensor’s knowledge, no Third Party has infringed or misappropriated any of the Licensed Rights or the Sublicensed Rights; 

 

(j) all inventors of any inventions included within the Licensed Serenity Patent Rights and, to the knowledge of Licensor, the Licensed CPEX Patent Rights and the Licensed Reprise Patent Rights have assigned their entire right, title, and interest in and to such inventions and the corresponding patents and patent applications to Licensor, Reprise, or CPEX, as applicable, and have been listed as inventors in the Licensed Serenity Patent Rights, the Licensed CPEX Patent Rights, and the Licensed Reprise Patent Rights, as applicable; 

 

(k) no agreements that Licensor or its Affiliates may have with any Third Party provide such Third Party with any rights of first offer, rights of first refusal, or any other rights to make, have made, use, conduct Clinical Studies for, sell, offer for sale, have sold, import, export, or otherwise Exploit the Product in the Field in the Territory or the right to use the Licensed Rights or the Sublicensed Rights in connection with the Exploitation of the Product in the Field in the Territory; and Licensor has received no notice from a Third Party of any suit, action, proceeding, or arbitration pending or threatened against it that the proposed terms and conditions of this Agreement, and the Parties’ performance in accordance therewith, do or shall conflict or interfere with in a manner resulting in a breach or default under, or other violation of, any agreements that Licensor or its Affiliates may have with any Third Party; 

 

to Licensor’s knowledge, (i) each of the CPEX License Agreement and the Reprise License Agreement is valid and enforceable in accordance with its terms, is in full force and effect, and there are no approvals or consents required to make it effective, (ii) Licensor has supplied Licensee with a true and correct copy of the CPEX License Agreement and the Reprise License Agreement , together with all amendments, waivers, or other changes thereto, (iii) Licensor has performed all material obligations required to be performed by it in connection with the CPEX License Agreement and the Reprise License Agreement, (iv) Licensor shall not materially breach and is not in material breach of the CPEX License Agreement or the Reprise License Agreement, (v) Licensor is not in receipt of any claim of default, cure notice, or show cause notice under the CPEX License Agreement or the Reprise License Agreement, and (vi) there is no current material breach or anticipated material breach by any other party to the CPEX License Agreement or the Reprise License Agreement; 

 

(m)

 (i) Licensor is the named sponsor of the First Approved NDA for the Product; and (ii) with respect to all Regulatory Documentation to obtain Regulatory Approvals for the Product in the Field: (A) the data, information and/or all other documents in Licensor’s or its Affiliates submissions were, are and shall be free from fraud or material falsity, and neither Licensor nor its Affiliates has made any material misrepresentation or omission in connection with such data; (B) the Regulatory Approvals have not been and will not be obtained either through bribery or the payment of illegal gratuities by Licensor; (C) the data, information and/or all other documents in Licensor’s or its Affiliates’ submissions are, were and shall be accurate and reliable for purposes of supporting approval of the submissions; and (D) the Regulatory Approvals shall be obtained without illegal or unethical behavior of any kind by Licensor or its Affiliates; provided that Licensor shall not be deemed to be in breach of this Section 10.2(m) if the violation of this Section 10.2(m) results from the action or omission of Licensee of Licensee’s Affiliates, Sublicensees, or contractors (other than Licensor); 

 

(n) Licensor believes in good faith, based on the information set forth in Schedule 10.2(n), that FDA will consider amending or supplementing the First Approved NDA (or the related IND) in the manner described in Schedule 10.2(n); provided, however, that Licensor cannot assure that FDA will approve such amendment or supplement. 

 

(o) except as expressly permitted hereunder, Licensor agrees not to, and agrees to cause its Affiliates and Sublicensees not to (i) assign, transfer, convey or otherwise encumber any right, title or interest in or to the Licensed Rights, the Sublicensed Rights, or any Regulatory Approvals and Documentation in respect of the Product, (ii) grant in any manner any license or other right, title or interest in or to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and Documentation in respect of the Product, or (iii) agree to or otherwise become bound by any covenant not to sue for any infringement, misuse or other action or inaction with respect to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and Documentation in respect of the Product; and

 

(p) other than the CPEX License Agreement, the Reprise License Agreement, the Renaissance Supply Agreements, and the other Third Party Supply Agreements, Licensor and/or its Affiliates have not entered into any agreements with any Third Party, pursuant to which any Third Party has granted to Licensor, or Licensor has granted to any Third Party, any rights to licenses to, in or under any of the Licensed Rights or the Sublicensed Rights or other intellectual property rights that relate to the Product, or relating to the manufacture of the Product.

 

10.3 Additional Representations, Warranties, and Covenants of Licensee. Licensee hereby represents, warrants, and covenants to Licensor, as of the Effective Date and except as otherwise stated in Schedule 10.3, that: 

 

(a) if, during the term of this Agreement Licensee has reason to believe that it or any of its employees, officers, subcontractors, or consultants rendering services relating to the Product: (i) is or will be debarred or convicted of a crime under 21 U.S.C. Section 335a, or (ii) is or will be under indictment under said Section 335a, then Licensee shall immediately notify Licensor in writing; 

 

 (b) as of the Effective Date, there is no legal, administrative, arbitration, or other proceeding, suit, claim, or action of any nature, judgment, decree, decision, injunction, writ, or order pending or, to the knowledge of Licensee’s senior management, threatened by, against Licensee regarding this Agreement, whether at law or in equity, before or by any Third Party; and Licensee shall provide notice of any of the foregoing to the extent it affects Licensee’s performance of its obligations under this Agreement; 

 

(c) except for information provided by Licensor, its Affiliates or Sublicensees: (i) the data and information in Licensee’s submissions and modifications of Regulatory Documentation relating to the Product shall be free from fraud or material falsity; (ii) Regulatory Approvals for the Product hereafter obtained will not be obtained either through bribery or the payment of illegal gratuities by Licensee; (iii) the data and information in Licensee’s submissions and modifications of any Regulatory Documentation shall be accurate and reliable; and (iv) any such the Regulatory Approvals will be obtained without illegal or unethical behavior of any kind by Licensee; provided that Licensee shall not be deemed to be in breach of this Section 10.3(c) if the violation of this Section 10.3(c) results from the action or omission of Licensor or its Affiliates, Sublicensees (other than Licensee), or contractors; and

 

(d) except as expressly permitted hereunder, Licensee agrees not to, and agrees to cause its Affiliates and Sublicensees not to (i) assign, transfer, convey or otherwise encumber any right, title or interest in or to the Licensed Rights, the Sublicensed Rights, or any Regulatory Approvals and Documentation in respect of the Product, (ii) grant in any manner any license or other right, title or interest in or to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and Documentation in respect of the Product, (iii) agree to or otherwise become bound by any covenant not to sue for any infringement, misuse or other action or inaction with respect to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and Documentation in respect of the Product, or (iv) bring any action or proceeding or otherwise assert any claim under any Applicable Law in the event any licensee (or sublicensee or any entity or person acting on its behalf) initiates any proceeding or otherwise assert any claim in any court, administrative agency, or other forum with jurisdiction over such proceeding or claim, that any of the Licensed Rights or Sublicensed Rights are invalid, unenforceable, or not infringed, violated, or misappropriated. In the event that Licensee or any Affiliate or Sublicensee of Licensee initiates any proceeding or otherwise asserts any claim in violation of clause (iv) of this Section 10.3, and the result thereof is a final decision, ruling, holding, award, or other disposition to the effect that any of the Licensed Rights or Sublicensed Rights are valid, enforceable, or infringed, violated, or misappropriated, then each of the royalty rates set forth in the table in Section 8.3(a) will each be increased by [***] and the party initiating such proceeding or otherwise asserting such claim shall pay the attorneys’ fees and expenses incurred by Licensor in defending against such proceeding or claim.

 

10.4 Inaccuracies. Without limiting either Party’s rights and remedies at law, in equity or under this Agreement, if, at any point in time (not just at the times when the warranties are deemed granted), either Party becomes aware of any inaccuracies in the foregoing warranties and representations, such Party shall promptly notify the other Party of such inaccuracies, with a detailed written explanation.

 

KASAN_기술이전, 특허 라이선스 계약서에서 진술 및 보증조항 REPRESENTATIONS AND WARRANTI

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.20 16:19
Trackback 0 : Comment 0

댓글을 달아 주세요


 

KASAN_[NDA분쟁] 비밀보호계약, 비밀유지약정, NDA, CDA에서 비밀보호대상 조항 위반여부 쟁점 미국소송

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.20 15:00
Trackback 0 : Comment 0

댓글을 달아 주세요


 

사안의 개요 및 쟁점

(1) 외국회사 특허권자 vs 국내회사 특허라이선스 체결

(2)  특허발명방법발명, 특허권자로부터 통상실시권 획득

(3)  상실시권자, 국내회사의 요청으로 특허발명의 전용품 마찰교반용접기를 제작하여 통상실시권자에게 납품한 행위

(4) 쟁점 - 특허권의 간접침해 해당여부

 

법원 판단간접침해 해당하지 않음

 

대법원 2017290095 판결요지

 

특허법 제127조 제2호는 특허가 방법의 발명인 경우 그 방법의 실시에만 사용하는 물건을 생산양도대여 또는 수입하거나 그 물건의 양도 또는 대여의 청약을 하는 행위를 업으로서 하는 경우에는 특허권 또는 전용실시권을 침해한 것으로 본다고 규정하고 있다. 이러한 간접침해 제도는 어디까지나 특허권이 부당하게 확장되지 아니하는 범위에서 그 실효성을 확보하고자 하는 것이다(대법원 2015. 7. 23. 선고 201442110 판결 등 참조).

 

방법의 발명(이하방법발명이라고 한다)에 관한 특허권자로부터 허락을 받은 실시권자가 제3자에게 그 방법의 실시에만 사용하는 물건(이하전용품이라고 한다)의 제작을 의뢰하여 그로부터 전용품을 공급받아 방법발명을 실시하는 경우에 있어서

 

그러한 3자의 전용품 생산양도 등의 행위를 특허권의 간접침해로 인정하면, 실시권자의 실시권에 부당한 제약을 가하게 되고, 특허권이 부당하게 확장되는 결과를 초래한다.

 

또한, 특허권자는 실시권을 설정할 때 제3자로부터 전용품을 공급받아 방법발명을 실시할 것까지 예상하여 실시료를 책정하는 등의 방법으로 당해 특허권의 가치에 상응하는 이윤을 회수할 수 있으므로, 실시권자가 제3자로부터 전용품을 공급받는다고 하여 특허권자의 독점적 이익이 새롭게 침해된다고 보기도 어렵다.

 

따라서 방법발명에 관한 특허권자로부터 허락을 받은 실시권자가 제3자에게 전용품의 제작을 의뢰하여 그로부터 전용품을 공급받아 방법발명을 실시하는 경우에 있어서 그러한 제3자의 전용품 생산, 양도 등의 행위는 특허권의 간접침해에 해당한다고 볼 수 없다.

 

KASAN_특허라이선스 계약에서 Licensee의 주문에 따라 특허발명의 전용품을 제조, 납품한 행위 – 특허간접침

 

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.20 09:37
Trackback 0 : Comment 0

댓글을 달아 주세요


 

15. MISCELLANEOUS.

15.1 Agency. Neither Party is, nor shall be deemed to be, an employee, agent, co-venturer, or legal representative of the other Party for any purpose, except as expressly set forth herein. No Party shall be entitled to enter into any contracts in the name of, or on behalf of the other Parties, nor shall either Party be entitled to pledge the credit of the other Parties in any way or hold itself out as having the authority to do so.

 

15.2 Assignment. Except as expressly provided in this Agreement, neither Party may assign any rights or delegate any duties under this Agreement to any Third Party without the prior written consent of the other Party; provided, however, that (a) Licensor may freely assign its right to receive any payments hereunder without such consent of Licensee, (b) in the case where either Party seeks to assign this Agreement as a whole to an Affiliate or to a Successor in connection with a Change of Control of such Party or of that part of such Party’s business to which this Agreement relates, such consent shall not be unreasonably withheld, delayed, or conditioned, provided that such Party provides written notice to the other Party of such Change of Control and such Successor agrees in writing to be bound as such Party hereunder. This Agreement shall be binding upon and inure to the successors and permitted assignees of the Parties and the name of a Party appearing herein shall be deemed to include the names of such Party’s Successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment or transfer not in accordance with this Section 15.2 shall be null and void.

 

15.3 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 

15.4 Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been given: (a) when personally delivered or sent by confirmed facsimile or email (with hard copy to follow); (b) one (1) Business Day after sent by reputable overnight express courier (charges prepaid); or (c) five (5) Business Days following mailing by certified or registered mail, postage prepaid and return receipt requested. Unless another address is specified in writing, such notices to Licensor or Licensee shall be sent to the addresses indicated below:

 

15.5 Amendment. No amendment, modification, or supplement of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party.

 

15.6 Waiver. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party.

 

15.7 Counterparts; Electronic Delivery. This Agreement may be executed simultaneously in two counterparts, either of which need not contain the signature of more than one Party but both such counterparts taken together shall constitute one and the same agreement. Signatures to this Agreement transmitted by facsimile, by email in “portable document format” (“.pdf”), or by any other electronic means intended to preserve the original graphic and pictorial appearance of this Agreement shall have the same effect as physical delivery of the paper document bearing original signature.

 

15.8 Governing Law; Dispute Resolution.

(a) This Agreement shall be governed by and interpreted in accordance with the substantive laws of the State of New York, U.S.A. without regard to its or any other jurisdiction’s choice of law rules that would result in the application of the laws of any jurisdiction other than the State of New York, U.S.A.

 

(b) Except as otherwise provided in this Agreement, in the event of any dispute, controversy, or claim (“Dispute”) between the Parties in connection with this Agreement, the construction hereof, or the rights, duties or liabilities of either Party under this Agreement, the Parties shall first attempt in good faith to resolve such Dispute by negotiation and consultation between themselves. In the event that such Dispute is not resolved on an informal basis within ten (10) Business Days after one Party provides notice to the other Party of such Dispute, either Party providing such notice may, by written notice to the other Party refer such Dispute to the other Party for attempted resolution by good faith negotiation by the Chief Executive Officers or President of Licensor and the Chief Executive Officer, President or an Executive Vice President within thirty (30) days after such notice is received. In the event that any such Dispute is not resolved under the foregoing provisions, each Party may, at its sole discretion, seek resolution of such Dispute in accordance with Section 15.8(c). Any Disputes of the type described in Section 3.2(i) shall first be subject to the dispute resolution mechanism set forth in Section 3.2(i) before being subject to this Section 15.8.

 

(c) In the event such officers of the Parties are not able to resolve any such Dispute, either Party may at any time after such thirty (30) day period submit such Dispute to be finally settled by arbitration administered in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”) in effect at the time of submission. The arbitration shall be heard and determined by three (3) arbitrators. Each such Party shall each appoint one arbitrator and the third arbitrator shall be selected by the two Party-appointed arbitrators, or, failing agreement within thirty (30) days following the date of receipt by the respondent of the claim, by the AAA. Such arbitration shall take place in New York, NY. The arbitration award so given shall be a final and binding determination of the dispute, shall be fully enforceable in any court of competent jurisdiction, and shall not include any damages expressly prohibited by Section 12.1. The Parties agree that all applicable statutes of limitation and time-based defenses (such as estoppel and laches) shall be tolled while the dispute resolution procedures set forth in this Section 15.8(c) are pending.

 

(d) Notwithstanding anything herein to the contrary, nothing in this Section 15.8 shall preclude either Party from seeking interim or provisional relief, including a temporary restraining order, preliminary injunction or other interim equitable relief concerning a Dispute, including in a court of law, if necessary to protect the interests of such Party. This Section 15.8 shall be specifically enforceable.

 

(e) Notwithstanding the foregoing, any disputes regarding the validity, scope or enforceability of Patent Rights or trademarks shall be submitted to a court of competent jurisdiction in the territory in which such rights apply.

 

15.10 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under Applicable Laws, but if any provision of this Agreement is held to be prohibited by or invalid under Applicable Laws, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. In the event of such invalidity, the Parties shall seek to agree on an alternative enforceable provision that preserves the original purpose of this Agreement.

 

15.11 Compliance with Applicable Laws. Each Party will comply with all Applicable Laws in performing its obligations and exercising its rights hereunder.

 

15.12 Remedies. The exercise of any remedies hereunder shall be cumulative and in addition to and not in limitation of any other remedies available to such Party at law or in equity.

 

15.13 Force Majeure. Neither Party shall be liable for delay or failure in the performance of any of its obligations hereunder if such delay or failure is due to causes beyond its reasonable control, including, without limitation, acts of nature, fires, earthquakes, strikes and labor disputes, acts of war, terrorism, or civil unrest (“Force Majeure”); provided that the affected Party promptly notifies the other Party and further provided that the affected Party shall use its commercially reasonable efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence, and shall continue performance with the utmost dispatch whenever such causes are removed. In the event any such Force Majeure event continues for three (3) months or more, the unaffected Party shall have the right to terminate this Agreement, effective as of the date of delivery of notice, which notice shall not be delivered prior to the end of such three (3) month period.

 

15.14 Interpretation. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provisions.

 

15.15 Construction. In construing this Agreement, unless expressly specified otherwise: (a) unless otherwise specifically provided, any references to Articles, Sections, Exhibits, Schedules, and Appendices are to articles in, sections of, and exhibits, schedules and appendices to, this Agreement; (b) except where the context otherwise requires, use of either gender includes the other gender and use of the singular includes the plural and vice versa; (c) headings and titles are for convenience only and do not affect the construction or interpretation of this Agreement; (d) any list or examples following the word “including” shall be interpreted without limitation to the generality of the preceding words; (e) the words “herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof; (f) except where the context otherwise requires, the word “or” is used in the inclusive sense; (g) all references to “dollars” or “$” herein shall mean US Dollars; (h) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (i) any reference to any Applicable Laws herein shall be construed as referring to such Applicable Laws as from time to time enacted, repealed or amended, and (j) any reference herein to any person or entity shall be construed to include the person’s or entity’s successors and assigns.

 

15.16 Entire Agreement of the Parties. This Agreement and the exhibits attached hereto constitute and contain the complete, final, and exclusive understanding and agreement of the Parties, and cancel and supersede any and all prior and contemporaneous negotiations, correspondence, understandings, and agreements, whether oral or written, between the Parties respecting the subject matter hereof, including without limitation the Confidentiality Agreement, and neither Party shall be liable or bound to any other Party in any manner by any representations, warranties, covenants, or agreements except as specifically set forth herein or therein. Nothing in this Agreement, express or implied, is intended to confer upon either Party, other than the Parties and their respective successors and assigns, any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided herein. To the extent that anything set forth in an exhibit attached hereto conflicts with the terms of this Agreement, the terms of this Agreement shall control.

 

KASAN_기술이전, 라이선스 등 영문계약서에 사용되는 일반조항 GENERAL PROVISIONS 계약조항 샘플.p

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.18 10:00
Trackback 0 : Comment 1

댓글을 달아 주세요

  1. 영문계약서 2019.08.29 21:35 [댓글주소] [수정/삭제] [댓글에 댓글달기]

    영문계약서 때문에 골치아픈데
    많은도움 됐습니다
    좋은글 많이 부탁드려요 감사해요


 

3. JOINT STEERING COMMITTEE AND ALLIANCE MANAGERS.

3.1 Generally.

(a) Joint Steering Committee. Licensor and Licensee shall form the Joint Steering Committee. The JSC will have only such powers as are specifically delegated to it in this Agreement, and such powers shall be subject to the terms and conditions set forth in this Agreement.

 

(b) JSC Subcommittees. The JSC is hereby authorized to appoint one or more JSC Subcommittees to which the JSC may assign responsibility for specific matters (including, without limitation, matters arising with respect to Development, Commercialization, and Manufacturing. Each JSC Subcommittee will have only such powers as are specifically delegated to it by the JSC, and the delegation of any such powers to any JSC Subcommittee shall be subject to the terms and conditions set forth in this Agreement.

 

(c) Limitation of Power of JSC and JSC Subcommittees. Without limiting the generality of Sections 3(a) and 3(b), neither the JSC nor any JSC Subcommittee shall have any power to amend this Agreement or bind or incur liability on behalf of either Party without such Party’s express prior written authorization.

 

(d) Compliance with JSC and JSC Subcommittee Decisions. Each Party will comply with the decisions of the JSC and any JSC Subcommittee to the extent such decisions arise from the JSC or such JSC Subcommittee, as applicable, carrying out its powers and responsibilities as set forth in this Agreement and not otherwise inconsistent with the terms and conditions of this Agreement. Notwithstanding the foregoing, and is expressly set forth herein, Licensee shall have the sole and absolute right and discretion to decide matters related to the Commercialization, Manufacturing, or Development of the Product.

 

3.2 Membership and Governance of JSC and JSC Subcommittees.

(a) Membership.

(i) The JSC will be comprised of six (6) members who, except as otherwise provided in clause (iii) of this Section 3.2(a), are employees of the Parties (each a “JSC Member”), with three (3) JSC Members designated by Licensor and three (3) JSC Members designated by Licensee.

(ii) Each JSC Subcommittee will be comprised of the total number of members (each a “JSC Subcommittee Member”) as is designated by the JSC in forming such JSC Subcommittee, with the number of JSC Subcommittee Members appointed to such JSC Subcommittee from each Party to be designated by the JSC in forming such JSC Subcommittee. In determining the number of JSC Subcommittee Members to serve on any JSC Subcommittee formed by the JSC, the JSC will provide that the number of such JSC Subcommittee Members to be designated by each Party will be reasonable with respect to the experience and expertise of the human resources of each such Party in respect of the matters for which such JSC Subcommittee is responsible.

(iii) Each of Licensor and Licensee, upon prior written notice to the other Party, may (i) replace each person such Party has designated as a JSC Member or a JSC Subcommittee Member for any reason at any time, upon prior written notice to the other Party, (ii) designate a substitute for each person such Party has designated as a JSC Member or JSC Subcommittee Member, and (iii) appoint non-employees of such Party as JSC Members and JSC Subcommittee Members only upon the prior consent and approval of the other Party.

 

(b) Decision-Making. While the JSC and each JSC Subcommittee will seek to decide matters under their respective consideration by consensus of all of its members, Licensee reserves the right to decide each such matter in its sole and absolute discretion.

 

(c) Meetings. The JSC and each JSC Subcommittee will meet as agreed upon by the JSC Members or the applicable JSC Subcommittee Members, respectively, in person or by teleconference or video-teleconference; provided that the first meeting of the JSC Committee or such JSC Subcommittee, as applicable, will be within ninety (90) days after the Effective Date.

 

(d) Observers. Except for matters in respect of which the JSC or any JSC Subcommittee needs to meet in executive session, the meetings of the JSC and any JSC Subcommittee may be attended by non-Member observers at the invitation of an executive officer of either Party (the “Inviting Party”), provided that (i) the Inviting Party provides reasonable prior notice of such invitation to the other Party, (ii) the other Party has consented to such invitation in advance of the applicable meeting, which such consent shall not be unreasonably withheld, delayed or conditioned and (iii) any such observer has agreed in writing to obligations to safeguard the confidentiality and restrictions on use of Confidential Information that are no less restrictive than the obligations in Section 13.2.

 

(e) Chairperson.

(i) Of JSC. At the first meeting of the JSC following the Effective Date and at the first meeting of the JSC in each calendar year beginning after the Effective Date, the JSC Members will select a chairperson to serve until such person’s successor has been designated in accordance herewith. The chairperson of the JSC shall rotate annually between JSC Members designated by Licensor and those designated by Licensee. The first chairperson of the JSC shall be selected from the JSC Members designated by the Licensee.

 

(ii) Of Each JSC Subcommittee. Each JSC Subcommittee shall have a chairperson appointed in accordance with the directions of the JSC in establishing such JSC Subcommittee.

 

(f) Secretary.

(i) Of JSC. The chairperson of the JSC shall designate a secretary of the JSC who will be responsible for calling meetings, preparing and circulating an agenda in advance of each meeting, and preparing and circulating minutes within thirty (30) days after each meeting of such committee setting forth, among other things, a description, in reasonable detail, of the discussions at the meeting and a list of any actions, decisions or determinations approved by the JSC. Such minutes shall be effective only after being approved by both Parties. Definitive minutes of all committee meetings shall be finalized no later than sixty (60) days after the meeting to which the minutes pertain.

(ii) Of Each JSC Subcommittee. Each JSC Subcommittee shall have a secretary appointed in accordance with the directions of the JSC in establishing such JSC Subcommittee.

 

(g) Term of JSC and JSC Subcommittees.

(i) The JSC shall continue to exist for the Term of this Agreement or upon its termination upon mutual agreement of the Parties.

(ii) Each JSC Subcommittee shall continue to exist for the term to be set forth by the JSC in establishing such JSC Subcommittee, but in no event for a period extending beyond the Term of this Agreement

 

(h) Alliance Managers.

(i) Each of Licensor and Licensee shall appoint an Alliance Manager, who shall be an individual authorized to act as such Party’s point of contact for communications between and among the Parties relating to the Commercialization, Manufacturing and Supply, and any Development Activities contemplated by this Agreement. Each Party may change its designated Alliance Manager from time to time upon written notice to the other Party. The Alliance Manager of a Party may designate a substitute to temporarily perform the functions of that Alliance Manager by written notice to the other Party.

(ii) Each Alliance Manager shall be charged with creating and maintaining a collaborative work environment between and among the Parties and within the JSC and each JSC Subcommittee.

(iii) Each Alliance Manager will also: (i) be the point of first referral in all matters of conflict resolution; (ii) identify and bring disputes to the attention of the JSC or the relevant JSC Subcommittee, as applicable, in a timely manner; (iii) plan and coordinate cooperative efforts and internal and external communications; and (iv) take responsibility for ensuring that governance activities, such as the conduct of required JSC and JSC Subcommittee meetings and production of meeting minutes occur as set forth in this Agreement, and that relevant action items resulting from such meetings are appropriately carried out or otherwise addressed

(i) Dispute Resolution.

(i) In the event that any dispute arises with respect to matters falling within the scope of the role and the powers and responsibilities of the JSC or any JSC Subcommittee as set forth in or contemplated by this Article 3 or elsewhere in this Agreement, then either Licensor or Licensee or any of the Members of such Committee may notify the Alliance Managers of such disputed matter.

(ii) The Alliance Managers shall discuss in good faith any such disputed matter referred to them in accordance with Section 3.2(i)(i). If the Alliance Managers are unable to resolve any such matter, either Licensor or Licensee may refer the matter to the Chief Executive Officer or President of Licensor and the Chief Executive Officer, President, or an Executive Vice President of Licensee, which such two individuals shall meet at an agreed location or by telephone to resolve the matter within twenty (20) days after the meeting at which such matter arose.

(iii) If such two officers of the Parties are unable to resolve the disputed matter so referred to them in accordance with Section 3.2(i)(ii) within an additional thirty (30) day period, then the following procedures shall apply:

(A) in the case of matters with respect to which Licensee is authorized hereunder to decide in its sole and absolute discretion, including, without limitation, any Commercialization or Manufacturing and Supply matter, Licensee shall have final decision-making rights with respect thereto and shall promptly provide written notice to Licensor of its final position regarding such matter and Licensor will comply with the position taken by Licensee on such matter unless compliance with such position would result in the incurrence of a direct material financial expenditure or imposition of some other non-financial burdensome obligation upon Licensor that would be greater than would have been the case absent compliance with such position, which in such case shall be referred for dispute resolution under Section 15.8 and

(B) in the case of matters with respect to which Licensee is not authorized hereunder to decide such matters in its sole and absolute discretion, such matters shall be referred for dispute resolution under Section 15.8.

 

3.3 Committee Oversight of Commercialization Activities.

(a) Role. The JSC and any JSC Subcommittee established for the purpose of oversight of Commercialization Activities, will monitor, assess, and make recommendations to Licensee in respect of the Commercialization of the Product contemplated in Article 4 of this Agreement.

 

(b) Powers and Responsibilities. With respect to Product Commercialization Activities, the powers and responsibilities of the JSC and any JSC Subcommittee established for the purpose of oversight of such Commercialization Activities are limited to the matters set forth in this Section 3.3 and Article 4. Neither the JSC nor any JSC Subcommittee shall have the power to amend, modify, or waive compliance with this Agreement with respect to Commercialization Activities required to be undertaken by Licensee under this Agreement, including, without limitation, the Commercialization Plans for the Product and any Indications. Notwithstanding the foregoing, Licensee reserves the right to decide each such Commercialization matter in its sole and absolute discretion, including amending or modifying any Commercialization Plan.

 

(c) Annual Review of Commercialization Plan. On an annual basis, beginning in the first full Calendar Year following the Effective Date, no later than sixty (60) days before the end of such Calendar Year, the JSC or any JSC Subcommittee responsible for oversight of Commercialization Activities will review, analyze, and comment on the Annual Commercialization Plan then in effect and any revisions thereto proposed by Licensee or Licensor, which such review, analysis, and comment will include, without limitation:

(i) an assessment of whether the Commercialization Activities contemplated by the Annual Commercialization Plan for the then current Calendar Year have been successfully undertaken and have achieved or are achieving the strategic objectives set forth in the Commercialization Plan;

(ii) an assessment of whether the strategic objectives set forth in the Annual Commercialization Plan, together with any revisions then proposed by Licensee or Licensor, continue to reflect the best interests of the Parties;

(iii) the submission to Licensee of any recommended revisions to the Annual Commercialization Plan then in effect and any revisions then proposed by Licensee or Licensor, in order to reflect the aforementioned assessments.

 

(d) Regulatory Exclusivity. The JSC and any JSC Subcommittee responsible for oversight of Commercialization Activities shall monitor the process of applying for and securing Regulatory Exclusivity that may be available under the applicable Law of countries in the Territory, including, without limitation, any data or market exclusivity periods such as those periods listed in the FDA’s Orange Book. Each of Licensor and Licensee shall use Commercially Reasonable Efforts to cooperate with each other and to take such reasonable actions to obtain such Regulatory Exclusivity in each country in the Territory.

 

3.4 Oversight of Manufacturing and Supply Activities.

(a) Role. The JSC and any JSC Subcommittee responsible for oversight of Manufacturing and Supply Activities will monitor, assess, and make recommendations to Licensee in respect of the manufacture and supply of the Product as contemplated in Article 5 for purposes of Commercializing the Product for any Indications that are the subject of Regulatory Approvals and any Development Activities in respect of the Product for the PNE Indication, any Additional Indications and the Nocturia Indication throughout the Territory.

 

(b) Powers and Responsibilities. With respect to Product Manufacturing Activities, the powers and responsibilities of the JSC and any JSC Subcommittee responsible for oversight of such Manufacturing Activities are limited to the matters set forth in this Section 3.4 and Article 5. Neither the JSC nor any JSC Subcommittee shall have the power to amend, modify or waive compliance with this Agreement with respect to Manufacturing Activities required to be undertaken by Licensee under this Agreement, including, without limitation, the Manufacturing and Supply Plan for the Product. Notwithstanding the foregoing, Licensee reserves the right to decide each such manufacturing and supply matter in its sole and absolute discretion, including amending or modifying any Manufacturing and Supply Plan.

 

(c) Annual Review of Manufacturing and Supply Plan. On an annual basis, beginning in the first full Calendar Year following the Effective Date, no later than sixty (60) days before the end of such Calendar Year, the JSC or any JSC Subcommittee responsible for oversight of Manufacturing Activities will review, analyze, and comment on the Manufacturing and Supply Plan then in effect, and any revisions thereto proposed by Licensee or Licensor, which such review, analysis, and comment will include, without limitation:

(i) an assessment of whether the Manufacturing Activities contemplated by the Manufacturing and Supply Plan for the then current Calendar Year have been successfully undertaken and have achieved or are achieving the strategic objectives set forth in the Manufacturing and Supply Plan; and

(ii) an assessment of whether the strategic objectives set forth in the Manufacturing and Supply Plan, together with any revisions then proposed by Licensee or Licensor, continue to reflect the best interests of the Parties.

 

3.5 Oversight of Development Activities.

(a) Role. The JSC and any JSC Subcommittee responsible for oversight of any Development Activities contemplated in Article 6 of this Agreement will monitor such Development Activities. In this role the JSC or such JSC Subcommittee, as applicable, will (i) assist Licensee in overseeing any Development of, Clinical Studies for, and preparation and submission of Regulatory Documentation for obtaining Regulatory Approval of the Product contemplated by any Development Plan, including, without limitation, review of any relevant Regulatory Documents and Regulatory Documentation and (ii) provide a forum for sharing advice, progress, and results and documents, including, without limitation, relevant Clinical Study designs, protocols, study reports, and any other material information with respect to any such Development Activities.

 

(b) Powers and Responsibilities. With respect to any Product Development Activities, the powers and responsibilities of the JSC and any JSC Subcommittee responsible for oversight of such Development Activities are limited to the matters set forth in this Section 3.5 and Article 6. Neither the JSC nor any JSC Subcommittee shall have the power to amend, modify or waive compliance with this Agreement with respect to Development Activities, including, without limitation, any Development Plan in effect from time to time. Notwithstanding the foregoing, Licensee reserves the right to decide each such Development matter in its sole and absolute discretion, including amending or modifying any Development Plan.

 

(c) Annual Review of Development Plan. If Licensee determines to engage in any Product Development Activities in accordance with Article 6, on an annual basis, beginning in the first full Calendar Year following the Effective Date, no later than sixty (60) days before the end of such Calendar Year, the JSC and any JSC Committee responsible for oversight of Development Activities that Licensee may so determine to undertake in accordance with Article 6 will review, analyze, and comment on the Development Plan then in effect, and any revisions thereto proposed by Licensee or Licensor, which such review, analysis, and comment will include, without limitation:

(A) an assessment of whether the Development Activities contemplated by the Development Plan for the then current Calendar Year have been successfully undertaken and have achieved or are achieving the strategic objectives set forth in the Development Plan;

(B) an assessment of whether the strategic objectives set forth in the Development Plan, together with any revisions then proposed by Licensee or Licensor, continue to reflect the best interests of the Parties;

(C) the submission to Licensee of any recommended revisions to the Development Plan then in effect and any revisions then proposed by Licensee or Licensor, in order to reflect the aforementioned assessments.

 

KASAN_제약회사의 기술이전, 독점 라이선스, API 공급, 완제품 생산위탁, 완제품구매 계약서에서 개발, 생산,

 

[질문 또는 상담신청 입력하기]

 

 

작성일시 : 2019.05.17 13:00
Trackback 0 : Comment 0

댓글을 달아 주세요